KASID
Article category
- Page Path
- HOME > Article category > Article category
Original Articles
- Miscellaneous
- Vegetarianism as a protective factor for asymptomatic colonic diverticulosis in Asians: a retrospective cross-sectional and case-control study
- Jihun Bong, Hyoun Woo Kang, Hyeki Cho, Ji Hyung Nam, Dong Kee Jang, Jae Hak Kim, Jun Kyu Lee, Yun Jeong Lim, Moon-Soo Koh, Jin Ho Lee
- Intest Res 2020;18(1):121-129. Published online November 1, 2019
- DOI: https://doi.org/10.5217/ir.2019.00106
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
Dietary fiber intake is considered a protective factor for diverticular disease such as diverticulitis. However, evidence for an inverse connection between dietary fiber consumption and asymptomatic colonic diverticulosis is lacking. Specifically, few studies have investigated this subject in Asians with different presentations of diverticulosis. Therefore, we assessed the protective effects of a vegetarian diet for asymptomatic colonic diverticulosis in Buddhist monks who are obligatory vegetarians for spiritual reasons compared with the general population.
Methods
A retrospective, cross-sectional, case-control study was conducted in age- and sex-matched Buddhist monks and the general population who underwent colonoscopy for screening at a Korean health promotion center from August 2005 to June 2018. We compared the prevalence of asymptomatic diverticulosis between the 2 groups using a self-administered questionnaire.
Results
In this study, a total of 1,316 individuals were included (Buddhist monks of 658 and general population of 658) with a mean age of 52.6±9.5 years. The prevalence of asymptomatic diverticulosis in Buddhist monks was lower compared with the general population (6.7% [44/658] vs. 10.8% [71/658], P=0.008). Buddhist monks had a higher rate of high body mass index (BMI) and metabolic syndrome. By a multivariate regression analysis model, a nonvegetarian diet (odds ratio [OR], 1.82; 95% confidence interval [CI], 1.21–2.72, P=0.004), old age (OR, 4.53; 95% CI, 1.36–15.12; P=0.014), male sex (OR, 1.91; 95% CI, 1.28–2.85; P=0.002), and a high BMI (OR, 1.50; 95% CI, 1.01–2.23; P=0.047) were independent predictors of asymptomatic diverticulosis. Moreover, a nonvegetarian diet was associated with both right-sided and left-sided diverticulosis.
Conclusions
A nonvegetarian diet may increase a risk of asymptomatic colonic diverticulosis in Asians. -
Citations
Citations to this article as recorded by
- Association of Metabolic Syndrome Components and Colonic Diverticulosis in the Very Elderly: A Tertiary Health Network Study
Hammad Liaquat, Farah Harmouch, Nishit Patel, Zarian Prenatt, Jill Stoltzfus, Berhanu Geme, Noel Martins, Kimberly Chaput
Cureus.2024;[Epub] CrossRef - Not all acute colonic diverticulitis follows the same course: a potential risk for immunocompromised individuals
Yehyun Park
Intestinal Research.2023; 21(4): 415. CrossRef - Age, alcohol, sex, and metabolic factors as risk factors for colonic diverticulosis
Ye Yan, Jian-Sheng Wu, Shuang Pan
World Journal of Clinical Cases.2022; 10(1): 136. CrossRef - Diagnosis and Treatment of Colonic Diverticular Disease
You Sun Kim
The Korean Journal of Gastroenterology.2022; 79(6): 233. CrossRef - The prevalence of right‐sided colonic diverticulosis in a New Zealand population
Greg A. Turner, Michael J. O'Grady, Sajith C. Senadeera, Chris J. Wakeman, Andrew McCombie, Rachel V. Purcell, Frank A. Frizelle
ANZ Journal of Surgery.2021; 91(10): 2110. CrossRef - The Epidemiology and Etiology of Right-Sided Colonic Diverticulosis: A Review
Greg A. Turner, Michael J. O’Grady, Rachel V. Purcell, Frank A. Frizelle
Annals of Coloproctology.2021; 37(4): 196. CrossRef
- Association of Metabolic Syndrome Components and Colonic Diverticulosis in the Very Elderly: A Tertiary Health Network Study
- 7,054 View
- 233 Download
- 6 Web of Science
- 6 Crossref
- Functional bowel disorder
- Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease
- Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, Stamatis S Papadatos, Konstantinos Katsanos, Vasiliki Galani
- Intest Res 2020;18(1):115-120. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00125
-
Abstract
PDFPubReaderePub
- Background/Aims
Irritable bowel syndrome (IBS) is a common disease often considered as a functional intestinal disorder. Inflammation in IBS is a quite intriguing theory. The aim of this study was to investigate tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 expression in inflammatory bowel disease (IBD) patients, IBS patients and normal controls.
Methods
IBS and IBD patients along with normal controls were recruited in the study. In all groups, 2 pinch biopsies were taken at each of 3 anatomical sites (terminal ileum, cecum, and rectum). IBS patients were also subcategorized according to the syndrome clinical manifestations. Two monoclonal antibodies (mAb), TNF-α mAb and IL-6 mAb, and one polyclonal antibody IL-1β mAb were applied for immunohistochemical analysis.
Results
In IBD patients intensity of TNF-α and IL-1β were lower than in IBS patients or controls, while IL-6 was significantly increased comparing to the aforementioned groups. In IBS patients TNF-α was increased comparing to IBD patients or controls, while IL-6 and IL-1β were similar to controls. In IBS subgroups, TNF-α was lower in diarrhea predominant IBS patients and higher constipation predominant IBS patients. Differences among IBS subgroups regarding IL-6 and IL-1β were nonsignificant.
Conclusions
IL-6 seems to be the most important proinflammatory cytokine in IBD patients, while TNF-α could play a more significant role in IBS pathogenesis. -
Citations
Citations to this article as recorded by- Guardians at the Gate: Immune System in Gastrointestinal Diseases
Elena Layunta, Jose Emilio Mesonero, Eva Latorre
International Journal of Molecular Sciences.2024; 25(11): 5933. CrossRef - Novel Dairy Fermentates Have Differential Effects on Key Immune Responses Associated with Viral Immunity and Inflammation in Dendritic Cells
Dearbhla Finnegan, Claire Connolly, Monica A. Mechoud, Jamie A. FitzGerald, Tom Beresford, Harsh Mathur, Lorraine Brennan, Paul D. Cotter, Christine E. Loscher
Foods.2024; 13(15): 2392. CrossRef - The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome
Vlad Alexandru Ionescu, Gina Gheorghe, Teodor Florin Georgescu, Nicolae Bacalbasa, Florentina Gheorghe, Camelia Cristina Diaconu
Journal of Clinical Medicine.2024; 13(17): 5124. CrossRef - Morphological Changes of the Pituitary Gland in Patients with Irritable Bowel Syndrome Using Magnetic Resonance Imaging
Jessica Abou Chaaya, Jennifer Abou Chaaya, Batoul Jaafar, Lea Saab, Jad Abou Chaaya, Elie Al Ahmar, Elias Estephan
Journal of Imaging.2024; 10(9): 226. CrossRef - Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome
Qian Chen, Hua Zhang, Chang-Yue Sun, Qing-Ying He, Rui-Rong Zhang, Bin-Fei Luo, Zi-Hao Zhou, Xiao-Fan Chen
Molecular Medicine.2023;[Epub] CrossRef - Structural properties and anti-inflammatory activity of purified polysaccharides from Hen-of-the-woods mushrooms (Grifola frondosa)
Xiaoyi Liu, Shuai Chen, Huijuan Liu, Jiao Xie, K. M. Faridul Hasan, Qibing Zeng, Shaofeng Wei, Peng Luo
Frontiers in Nutrition.2023;[Epub] CrossRef - An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef - Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik
Molecules.2023; 28(13): 5081. CrossRef - Structure and Metabolic Activity of the Gut Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Combined with Functional Dyspepsia
Aleksandra Kovaleva, Elena Poluektova, Roman Maslennikov, Oxana Zolnikova, Oleg Shifrin, Anna Kudryavtseva, George Krasnov, Maria Fedorova, Anna Karchevskaya, Vladimir Ivashkin
Gastrointestinal Disorders.2023; 5(3): 296. CrossRef - NK cells vs. obesity: A tale of dysfunction & redemption
Conor De Barra, Donal O'Shea, Andrew E. Hogan
Clinical Immunology.2023; 255: 109744. CrossRef - Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders
Md Jahangir Alam, Jiande D. Z. Chen
Bioelectronic Medicine.2023;[Epub] CrossRef - Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review
Cristina Maria Marginean, Mihaela Popescu, Andrei Ioan Drocas, Sergiu Marian Cazacu, Radu Mitrut, Iulia Cristina Marginean, George Alexandru Iacob, Marian Sorin Popescu, Anca Oana Docea, Paul Mitrut
Gastrointestinal Disorders.2023; 5(4): 517. CrossRef - Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
Farrah Rasool Jaafar, Ahmed Abu-Raghif
Journal of Medicine and Life.2023; 16(8): 1165. CrossRef - Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
雅君 陈
Hans Journal of Food and Nutrition Science.2022; 11(01): 44. CrossRef - Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects
Yongfeng Zhang, Yaqin Zhang, Yang Zhao, Wanyue Wu, Weiqi Meng, Yulin Zhou, Ye Qiu, Chenliang Li
Molecular Medicine Reports.2022;[Epub] CrossRef - The Role of Neuro-Immune Interaction in Chronic Pain Conditions; Functional Somatic Syndrome, Neurogenic Inflammation, and Peripheral Neuropathy
Elaine Meade, Mary Garvey
International Journal of Molecular Sciences.2022; 23(15): 8574. CrossRef - Ameliorating effects of electroacupuncture on the low‐grade intestinal inflammation in rat model of diarrhea‐predominant irritable bowel syndrome
Xuemei Li, Kuiyu Ren, Xiaojuan Hong, Sha Guo, Shuguang Yu, Sha Yang
Journal of Gastroenterology and Hepatology.2022; 37(10): 1963. CrossRef - Healthy Sleep Every Day Keeps the Doctor Away
Cailan Lindsay Feingold, Abbas Smiley
International Journal of Environmental Research and Public Health.2022; 19(17): 10740. CrossRef - Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial
Seung Yong Shin, Sein Park, Jung Min Moon, Kisung Kim, Jeong Wook Kim, Jongsik Chun, Tae Hee Lee, Chang Hwan Choi
Journal of Neurogastroenterology and Motility.2022; 28(4): 642. CrossRef - Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy
S. N. Mekhdiyev, O. A. Mekhdieva, O. M. Berko
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2022; 32(4): 95. CrossRef - Effect of Heat-Killed Lactobacillus casei DKGF7 on a Rat Model of Irritable Bowel Syndrome
Gyeol Seong, Seungbaek Lee, Yang Won Min, Yeon Sil Jang, Hong Seog Kim, Eui-Joong Kim, So-Young Park, Cheol-Hyun Kim, Dong Kyung Chang
Nutrients.2021; 13(2): 568. CrossRef - A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis
Brianna M. Quinville, Natalie M. Deschenes, Alex E. Ryckman, Jagdeep S. Walia
International Journal of Molecular Sciences.2021; 22(11): 5793. CrossRef - Lactiplantibacillus plantarum 299v (LP299V®): three decades of research
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson, N. Larsson
Beneficial Microbes.2021; 12(5): 441. CrossRef - Immunohistochemical Study of Adhesion Molecules in Irritable Bowel Syndrome
Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, Stamatis S. Papadatos, Antonios Klaroudas, Konstantinos Katsanos, Vasiliki Galani
Advanced Biomedical Research.2021; 10(1): 21. CrossRef - TNF-α, IL-17, and IL-22 production in the rectal mucosa of nonceliac wheat sensitivity patients: role of adaptive immunity
Pasquale Mansueto, Diana Di Liberto, Francesca Fayer, Maurizio Soresi, Girolamo Geraci, Antonio Giulio Giannone, Aurelio Seidita, Alberto D’Alcamo, Francesco La Blasca, Marianna Lo Pizzo, Ada Maria Florena, Francesco Dieli, Antonio Carroccio
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(3): G281. CrossRef - Sudachinoid- and Ichangensin-Type Limonoids from Citrus junos Downregulate Pro-Inflammatory Cytokines
Jihun Shin, Hwa Young Song, Mina Lee
International Journal of Molecular Sciences.2020; 21(18): 6963. CrossRef - Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction
Anna Lebedeva, Wendy Fitzgerald, Ivan Molodtsov, Alexander Shpektor, Elena Vasilieva, Leonid Margolis
Scientific Reports.2020;[Epub] CrossRef - Lactoferrin in the Prevention and Treatment of Intestinal Inflammatory Pathologies Associated with Colorectal Cancer Development
Antimo Cutone, Giusi Ianiro, Maria Stefania Lepanto, Luigi Rosa, Piera Valenti, Maria Carmela Bonaccorsi di Patti, Giovanni Musci
Cancers.2020; 12(12): 3806. CrossRef
- Guardians at the Gate: Immune System in Gastrointestinal Diseases
- 6,641 View
- 187 Download
- 27 Web of Science
- 28 Crossref
- Colorectal neoplasia
- Microvascular density under magnifying narrow-band imaging endoscopy in colorectal epithelial neoplasms
- Takahiro Gonai, Keisuke Kawasaki, Shotaro Nakamura, Shunichi Yanai, Risaburo Akasaka, Kunihiko Sato, Yousuke Toya, Kensuke Asakura, Jun Urushikubo, Yasuko Fujita, Makoto Eizuka, Noriyuki Uesugi, Tamotsu Sugai, Takayuki Matsumoto
- Intest Res 2020;18(1):107-114. Published online November 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00061
-
Abstract
PDFPubReaderePub
- Background/Aims
Magnifying endoscopic classification systems, such as the Japan narrow-band imaging (NBI) Expert Team (JNET) classification, have been widely used for predicting the histologic diagnosis and invasion depth of colorectal epithelial tumors. However, disagreement exists among observers regarding magnifying endoscopic diagnosis, because these classification systems are subjective. We herein investigated the utility of endoscopic microvascular density (eMVD) calculated from magnifying NBI endoscopic images in colorectal tumors.
Methods
We reviewed magnifying NBI endoscopic images from 169 colorectal epithelial tumors (97 adenomas, 72 carcinomas/high-grade dysplasias) resected endoscopically or surgically. The eMVD on magnifying NBI endoscopic images was evaluated using image-editing software, and relationships between eMVD and clinical, endoscopic, and pathological findings were retrospectively analyzed.
Results
The eMVD in carcinomas (0.152 ± 0.079) was significantly higher than that in adenomas (0.119 ± 0.059, P< 0.05). The best cutoff value for distinguishing carcinoma from adenoma was 0.133. Sensitivity, specificity, and accuracy were 56.9%, 67.0%, and 62.7%, respectively. In addition, JNET type 2B tumors showed significantly higher eMVD (0.162 ± 0.079) compared to type 2A tumors (0.111 ± 0.050, P< 0.05).
Conclusions
The eMVD as determined by magnifying NBI endoscopy is considered to be a possible objective indicator for differentiating colorectal carcinomas from adenomas. -
Citations
Citations to this article as recorded by- Novel physiological analysis using blood flow velocity for colonic polyps: Pilot study
Eiji Kamba, Takashi Murakami, Naoki Tsugawa, Kei Nomura, Keiichi Haga, Yoichi Akazawa, Hirofumi Fukushima, Hiroya Ueyama, Kenshi Matsumoto, Tomoyoshi Shibuya, Takeshi Terai, Takashi Yao, Akihito Nagahara
Endoscopy International Open.2024; 12(06): E781. CrossRef - Feasibility of moxifloxacin and proflavine dual fluorescence imaging for detecting gastrointestinal neoplastic lesions: A prospective study
Kwangwoo Nam, Noseong Park, Seunghun Lee, Suil Jeon, Jungbin Lee, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jeong Hoon Lee, Do Hoon Kim, Ki Hean Kim, Seung‐Jae Myung
Lasers in Surgery and Medicine.2023; 55(4): 378. CrossRef - Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect
Zugang Yin, Chenhui Yao, Limin Zhang, Shaohua Qi
Frontiers in Medicine.2023;[Epub] CrossRef - Chicken skin mucosa surrounding small colorectal cancer could be an endoscopic predictive marker of submucosal invasion
Ying-Jie Zhang, Wu Wen, Fan Li, Yi Jian, Chuan-Ming Zhang, Meng-Xia Yuan, Ye Yang, Feng-Lin Chen
World Journal of Gastrointestinal Oncology.2023; 15(6): 1062. CrossRef - A review on self-healing featured soft robotics
Md. Ariful Islam, Labanya Talukder, Md. Firoj Al, Subrata K. Sarker, S. M. Muyeen, Prangon Das, Md. Mehedi Hasan, Sajal K. Das, Md. Manirul Islam, Md. Robiul Islam, Sumaya Ishrat Moyeen, Faisal R. Badal, Md. Hafiz Ahamed, Sarafat Hussain Abhi
Frontiers in Robotics and AI.2023;[Epub] CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intestinal Research.2022; 20(3): 281. CrossRef - Colonic Chicken Skin Mucosa Surrounding Colon Polyps Is an Endoscopic Predictive Marker for Colonic Neoplastic Polyps
Yu Mi Lee, Kyung Ho Song, Hoon Sup Koo, Choong-Sik Lee, Inseok Ko, Sang Hyuk Lee, Kyu Chan Huh
Gut and Liver.2022; 16(5): 754. CrossRef - Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef - Response to Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Istvan Racz, Andras Horvath, Zoltán Horvath
Clinical Endoscopy.2022; 55(5): 701. CrossRef - Photoacoustic endoscopy: A progress review
Heng Guo, Ying Li, Weizhi Qi, Lei Xi
Journal of Biophotonics.2020;[Epub] CrossRef - Diagnostic efficacy of the Japan Narrow-band-imaging Expert Team and Pit pattern classifications for colorectal lesions: A meta-analysis
Yu Zhang, Hui-Yan Chen, Xiao-Lu Zhou, Wen-Sheng Pan, Xin-Xin Zhou, Hang-Hai Pan
World Journal of Gastroenterology.2020; 26(40): 6279. CrossRef
- Novel physiological analysis using blood flow velocity for colonic polyps: Pilot study
- 6,593 View
- 115 Download
- 11 Web of Science
- 12 Crossref
- Colorectal neoplasia
- Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
- Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
- Intest Res 2020;18(1):96-106. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00092
-
Abstract
PDFPubReaderePub
- Background/Aims
We aimed to investigate the proportion of and risk factors for residual cancer and/or lymph node metastasis after surgery was performed because of high-risk pathological features in endoscopic resection specimen of suspected superficial submucosal colorectal cancer (SSMC).
Methods
We reviewed medical records of 497 patients (58.8 ± 9.8 years, 331 males) undergoing endoscopic resection of suspected SSMC. High-risk pathological features included: deep submucosal cancer invasion ≥ 1,000 μm; positive lymphovascular and/or perineural invasion; poorly differentiated adenocarcinoma; and positive resection margin. We investigated the occurrence of additional surgery and residual cancer and/or lymph node involvement in the surgical specimen.
Results
En bloc resection was performed in 447 patients (89.9%). High-risk pathological features were detected in 372 patients (74.8%). Additional surgery was performed in 336 of 372 patients with high-risk pathological features. Of these, 47 surgical specimens (14.0%) showed residual cancer and/or lymph node metastasis. Piecemeal resection was more common in those with residual cancer and/or lymph node involvement than those without (9/47 [19.1%] vs. 24/289 [8.3%], P= 0.032). Positive resection margin was also significantly associated with positive residual cancer and/or lymph node involvement. As the number of high-risk pathological features increased, the risk of regional lymph node metastasis increased proportionally (P= 0.002).
Conclusions
High-risk pathological features were frequently detected after endoscopic resection of suspected SSMC while residual cancer and/or lymph node metastasis were not commonly present in the additional surgical specimen. Further optimized strategy for proper endoscopic management of suspected SSMC is necessary. -
Citations
Citations to this article as recorded by- Curative criteria for endoscopic treatment of colorectal cancer
Lucille Quénéhervé, Mathieu Pioche, Jérémie Jacques
Best Practice & Research Clinical Gastroenterology.2024; 68: 101883. CrossRef - Early Rectal Cancer and Local Excision: A Narrative Review
Cecilia Binda, Matteo Secco, Luigi Tuccillo, Chiara Coluccio, Elisa Liverani, Carlo Felix Maria Jung, Carlo Fabbri, Giulia Gibiino
Journal of Clinical Medicine.2024; 13(8): 2292. CrossRef - Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens
Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang
Cancers.2024; 16(10): 1900. CrossRef - How secure can we expect the surveillance policies to be after the implementation in T1 polyps with carcinoma?
Cristina Mateos Sanchez, Elvira Quintanilla Lazaro, Luis Ramon Rabago
World Journal of Gastrointestinal Endoscopy.2024; 16(9): 502. CrossRef - Comment on " Positive fecal immunochemical test results are associated with non-colorectal cancer mortality"
Yong Eun Park
The Korean Journal of Internal Medicine.2023; 38(2): 264. CrossRef - Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma
Hyun Jin Bae, Hoyeon Ju, Han Hee Lee, Jinsu Kim, Bo-In Lee, Sung Hak Lee, Daeyoun David Won, Yoon Suk Lee, In Kyu Lee, Young-Seok Cho
Surgical Endoscopy.2023; 37(2): 1231. CrossRef - Comparative Cost Analysis Between Endoscopic Resection and Surgery for Submucosal Colorectal Cancer
Soo Min Noh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, In Ja Park, Seok-Byung Lim, Jeong-Sik Byeon
Diseases of the Colon & Rectum.2023; 66(5): 723. CrossRef - Incidence of colonoscopy-related perforation and risk factors for poor outcomes: 3-year results from a prospective, multicenter registry (with videos)
Jieun Lee, Yoo Jin Lee, Jong Won Seo, Eun Soo Kim, Sung Kook Kim, Min Kyu Jung, Jun Heo, Hyun Seok Lee, Joon Seop Lee, Byung Ik Jang, Kyeong Ok Kim, Kwang Bum Cho, Eun Young Kim, Dae Jin Kim, Yun Jin Chung
Surgical Endoscopy.2023; 37(8): 5865. CrossRef - Usage trends of colorectal endoscopic submucosal dissection according to hospital types based on nationwide claims data
Ji Eun Na, Bohyoung Kim, Sung Hoon Jung, Arum Choi, Sukil Kim, Tae-Oh Kim
Medicine.2023; 102(43): e35514. CrossRef - Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis
Hao Dang, Nik Dekkers, Saskia le Cessie, Jeanin E. van Hooft, Monique E. van Leerdam, Philip P. Oldenburg, Louis Flothuis, Jan W. Schoones, Alexandra M.J. Langers, James C.H. Hardwick, Jolein van der Kraan, Jurjen J. Boonstra
Clinical Gastroenterology and Hepatology.2022; 20(2): e298. CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis
Liselotte W. Zwager, Barbara A.J. Bastiaansen, Nahid S.M. Montazeri, Roel Hompes, Valeria Barresi, Katsuro Ichimasa, Hiroshi Kawachi, Isidro Machado, Tadahiko Masaki, Weiqi Sheng, Shinji Tanaka, Kazutomo Togashi, Chihiro Yasue, Paul Fockens, Leon M.G. Moo
Gastroenterology.2022; 163(1): 174. CrossRef - Utility of artificial intelligence with deep learning of hematoxylin and eosin-stained whole slide images to predict lymph node metastasis in T1 colorectal cancer using endoscopically resected specimens; prediction of lymph node metastasis in T1 colorecta
Joo Hye Song, Yiyu Hong, Eun Ran Kim, Seok-Hyung Kim, Insuk Sohn
Journal of Gastroenterology.2022; 57(9): 654. CrossRef - Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intestinal Research.2022; 20(3): 281. CrossRef - Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: a multicenter cohort study
Jongbeom Shin, Eun Ran Kim, Hyun Joo Jang, Dong Hoon Baek, Dong-Hoon Yang, Bo-In Lee, Kwang Bum Cho, Jin Woong Cho, Sung-Ae Jung, Su Jin Hong, Bong Min Ko, Jung-Won Jeon, Weon Jin Ko, Sun Moon Kim, Young Dae Kim, Kim Chan Gyoo, Gwang Ho Baik, In Kyung Yoo
BMC Gastroenterology.2022;[Epub] CrossRef - Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef
- Curative criteria for endoscopic treatment of colorectal cancer
- 6,213 View
- 170 Download
- 16 Web of Science
- 16 Crossref
- Inflammatory bowel diseases
- Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
- Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
- Intest Res 2020;18(1):85-95. Published online July 19, 2019
- DOI: https://doi.org/10.5217/ir.2019.00055
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Patients with inflammatory bowel disease (IBD) are usually hospitalized because of aggravated gastrointestinal symptoms. Many clinicians empirically advise these patients to fast once they are admitted. However, there has been no evidence that maintaining a complete bowel rest improves the disease course. Therefore, we aimed to investigate the effects of fasting on disease course in admitted patients with IBD or intestinal Behçet’s disease.
Methods
A total of 222 patients with IBD or intestinal Behçet’s disease, who were admitted for disease-related symptoms, were retrospectively analyzed. We divided them into 2 groups: fasting group (allowed to take sips of water but no food at the time of admission) and dietary group (received liquid, soft, or general diet).
Results
On admission, 124 patients (55.9%) started fasting and 98 patients (44.1%) started diet immediately. Among patients hospitalized through the emergency room, a significantly higher proportion underwent fasting (63.7% vs. 21.4%, P<0.001); however, 96.0% of the patients experienced dietary changes. Corticosteroid use (P<0.001; hazard ratio, 2.445; 95% confidence interval, 1.506–3.969) was significantly associated with a reduction in the disease activity score, although there was no significant difference between the fasting group and the dietary group in disease activity reduction (P=0.111) on multivariate analysis.
Conclusions
In terms of disease activity reduction, there was no significant difference between the fasting and dietary groups in admitted patients with IBD, suggesting that imprudent fasting is not helpful in improving the disease course. Therefore, peroral diet should not be avoided unless not tolerated by the patient. -
Citations
Citations to this article as recorded by- Outcomes of dietary management approaches in active ulcerative colitis: A systematic review
Abigail Marsh, Sophie Rindfleish, Kalina Bennett, Anthony Croft, Veronique Chachay
Clinical Nutrition.2022; 41(2): 298. CrossRef - Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study
Mohamed Negm, Ahmed Bahaa, Ahmed Farrag, Rania M. Lithy, Hedy A. Badary, Mahmoud Essam, Shimaa Kamel, Mohamed Sakr, Waleed Abd El Aaty, Mostafa Shamkh, Ahmed Basiony, Ibrahim Dawoud, Hany Shehab
BMC Gastroenterology.2022;[Epub] CrossRef - Circadian Influences of Diet on the Microbiome and Immunity
Danping Zheng, Karina Ratiner, Eran Elinav
Trends in Immunology.2020; 41(6): 512. CrossRef
- Outcomes of dietary management approaches in active ulcerative colitis: A systematic review
- 13,665 View
- 267 Download
- 4 Web of Science
- 3 Crossref
- Inflammatory bowel diseases
- The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease
- Chan Hyung Lee, Hyuk Yoon, Dong Jun Oh, Jae Min Lee, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
- Intest Res 2020;18(1):79-84. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00107
-
Abstract
PDFPubReaderePub
- Background/Aims
Crohn’s disease is associated with altered body composition, such as low muscle mass, which can affect clinical outcomes. However, there are few studies regarding the effect of sarcopenia on prognosis of Crohn’s disease. In this study, we evaluated the body composition at the initial diagnosis of Crohn’s disease and analyzed the clinical meaning of sarcopenia.
Methods
We conducted a retrospective review of medical records of patients who were diagnosed as Crohn’s disease and underwent computed tomography within 3 months after diagnosis. Sarcopenia was defined as an L3 skeletal muscle index (SMI) of < 49 cm2/m2 for men and < 31 cm2/m2 for women. Outcomes such as need for hospitalization, surgery, use of steroids, immunomodulators and biologics were analyzed.
Results
A total of 79 patients (male, 73.4%; mean age, 29.9 years) were included and 40 patients (51%) were diagnosed as sarcopenia. C-reactive protein (CRP) level was correlated with sarcopenia (P= 0.044). Erythrocyte sedimentation rate (ESR) showed a tendency to decrease inversely with SMI (r = –0.320, P= 0.008) and hemoglobin and albumin tended to increase in proportion to SMI (hemoglobin: r = 0.271, P= 0.016 and albumin: r = 0.350, P= 0.002). However, there was no statistically significance in time-to-first-event analysis in aspects of sarcopenia.
Conclusions
Approximately 50% of patients with newly diagnosed as Crohn’s disease had sarcopenia. CRP levels were higher in the sarcopenia group and SMI correlated with ESR, hemoglobin, and albumin. However, none of prognostic values were demonstrated. -
Citations
Citations to this article as recorded by- Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
Pardhu B Neelam, Alka Sharma, Vishal Sharma
JGH Open.2024;[Epub] CrossRef - The association between hemoglobin level and sarcopenia in Chinese patients with Crohn’s disease
Nandong Hu, Jingjing Liu, Xifa Gao, Hongye Tang, Jiangchuan Wang, Zicheng Wei, Zhongqiu Wang, Xiaoli Yu, Xiao Chen
BMC Gastroenterology.2024;[Epub] CrossRef - Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
Gut and Liver.2024; 18(2): 294. CrossRef - Ultrasound muscle assessment for sarcopenia detection in inflammatory bowel disease: A prospective study
Giacomo Mulinacci, Lorena Pirola, Davide Gandola, Davide Ippolito, Chiara Viganò, Alice Laffusa, Camilla Gallo, Pietro Invernizzi, Silvio Danese, Sara Massironi
United European Gastroenterology Journal.2024; 12(5): 562. CrossRef - Causal associations between autoimmune diseases and sarcopenia-related traits: a bi-directional Mendelian randomization study
Chunlan Chen, Ying He
Frontiers in Genetics.2024;[Epub] CrossRef - The Relationship Between Intramural Fat Accumulation and Sarcopenia on MR Enterography Exams in Patients with Crohn’s Disease
Oktay Algin, Yasin Celal Güneş, Rasim Eren Cankurtaran, Seniha Corabay, Oyku Tayfur Yurekli
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2024;[Epub] CrossRef - The relationship between inflammatory bowel disease and sarcopenia-related traits: a bidirectional two-sample mendelian randomization study
Zhihuang Sun, Guangwei Liu, Jiajia Xu, Xianyu Zhang, Huahua Wei, Guobao Wu, Jian Jiang
Frontiers in Endocrinology.2024;[Epub] CrossRef - Association between sarcopenia and hemoglobin level: a systematic review and meta-analysis
Hui Wang, Ping Lin
Frontiers in Medicine.2024;[Epub] CrossRef - Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Digestive Diseases and Sciences.2023; 68(6): 2165. CrossRef - Nutritional Risk and Sarcopenia Features in Patients with Crohn’s Disease: Relation to Body Composition, Physical Performance, Nutritional Questionnaires and Biomarkers
Konstantinos Papadimitriou, Paraskevi Detopoulou, Konstantinos Soufleris, Gavriela Voulgaridou, Despoina Tsoumana, Panagiotis Ntopromireskou, Constantinos Giaginis, Ioanna P. Chatziprodromidou, Maria Spanoudaki, Sousana K. Papadopoulou
Nutrients.2023; 15(16): 3615. CrossRef - Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn’s disease cohort with penetrating disease, -ostomies and sarcopenia
Saskia Inniss, Konstantinos C. Fragkos, Lisa Whitley, Rachel Wimpory, Eleanor Rebello, Ana Lisboa, Tanvi Khetan, Jasmine Hassan, Kate Simpson, Anisha Bhagwanani, Roser Vega, Ioanna Parisi, Paul Harrow, Edward Seward, Sara McCartney, Stuart Bloom, Andrew M
Therapeutic Advances in Chronic Disease.2023;[Epub] CrossRef - Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics
Mauro Grova, Federica Crispino, Marcello Maida, Alessandro Vitello, Sara Renna, Angelo Casà, Lorenzo Tesè, Fabio Salvatore Macaluso, Ambrogio Orlando
Digestive and Liver Disease.2023; 55(7): 865. CrossRef - The effect of biological agent on body composition in patients with Crohn’s disease
Eun Jeong Choi, Dong Hoon Baek, Hong Sub Lee, Geun Am Song, Tae Oh Kim, Yong Eun Park, Chang Min Lee, Jong Hoon Lee
BMC Gastroenterology.2023;[Epub] CrossRef - Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease
Stephanie L. Gold, Maitreyi Raman, Bruce E. Sands, Ryan Ungaro, João Sabino
Alimentary Pharmacology & Therapeutics.2023; 57(11): 1216. CrossRef - Association between computed tomography‐assessed sarcopenia and mortality in patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis
Sung Soo Ahn, Yong‐Beom Park, Sang‐Won Lee
International Journal of Rheumatic Diseases.2023; 26(9): 1704. CrossRef - Imaging-based assessment of body composition in patients with Crohn’s disease: a systematic review
Wuli Tang, Gang Xie, Danni Wang, Ting Li, Yitao Ren, Junlin Li, Jiaxing Deng, Kang Li
International Journal of Colorectal Disease.2023;[Epub] CrossRef - Systematic review of sarcopenia in inflammatory bowel disease
Hala Fatani, Adina Olaru, Rebecca Stevenson, Waad Alharazi, Ayman Jafer, Philip Atherton, Matthew Brook, Gordon Moran
Clinical Nutrition.2023; 42(8): 1276. CrossRef - Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef - Magnetic Resonance Imaging Can Be Used to Assess Sarcopenia in Children with Newly Diagnosed Crohn’s Disease
Paola Blagec, Sila Sara, Ana Tripalo Batoš, Ivana Trivić Mažuranić, Ana Močić Pavić, Zrinjka Mišak, Iva Hojsak
Nutrients.2023; 15(17): 3838. CrossRef - Key genes of inflammation and Crohn’s disease severity identified via bioinformatics and clinical specimen analysis
Min Lu, Zhirui Zeng, Yongjian Ling, Qinsong Zhong, Zhiliang Mai, Hua Mao, Qian Wang
All Life.2023;[Epub] CrossRef - Research progress on the predictive role of sarcopenia in the course and prognosis of inflammatory bowel disease
Yang Liu, Linglin Tian
PeerJ.2023; 11: e16421. CrossRef - Characteristics of malnutrition according to Global Leadership Initiative on Malnutrition criteria in non-surgical patients with inflammatory bowel disease
Shanshan Huang, Yang Niu, Xiaowei Liu, Zhengye Gu, Aiyue Huang, Jiang Wu
Nutrition.2022; 94: 111514. CrossRef - Nutritional screening and assessment in inflammatory bowel disease
Arshdeep Singh, Catherine Wall, Arie Levine, Vandana Midha, Ramit Mahajan, Ajit Sood
Indian Journal of Gastroenterology.2022; 41(1): 5. CrossRef - Association Between Frailty or Sarcopenia and Adverse Outcomes in Inflammatory Bowel Disease: A Systematic Review
Katherine Bedard, Naheed Rajabali, Puneeta Tandon, Juan G. Abraldes, Farhad Peerani
Gastro Hep Advances.2022; 1(2): 241. CrossRef - Sarcopenia Is More Prevalent Among Inflammatory Bowel Disease Patients Undergoing Surgery and Predicts Progression to Surgery Among Medically Treated Patients
James P Campbell, Levi Teigen, Scott Manski, Brian Blumhof, Flavius F Guglielmo, Raina Shivashankar, Eugenia Shmidt
Inflammatory Bowel Diseases.2022; 28(12): 1844. CrossRef - Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
Ashwin N Ananthakrishnan, Gilaad G Kaplan, Charles N Bernstein, Kristin E Burke, Paul J Lochhead, Alexa N Sasson, Manasi Agrawal, Jimmy Ho Tuan Tiong, Joshua Steinberg, Wolfgang Kruis, Flavio Steinwurz, Vineet Ahuja, Siew C Ng, David T Rubin, Jean-Frederi
The Lancet Gastroenterology & Hepatology.2022; 7(7): 666. CrossRef - Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future
Adam S. Faye, Tasnin Khan, Sandhya Cautha, Bharati Kochar
Current Treatment Options in Gastroenterology.2022; 20(3): 250. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease: Should It Be Considered?
Simon Reider, Lukas Binder, Stefan Fürst, Stefan Hatzl, Andreas Blesl
Cells.2022; 11(21): 3463. CrossRef - Serial Changes in Body Composition and the Association with Disease Activity during Treatment in Patients with Crohn’s Disease
Ji Young Lee, Kyung Won Kim, Yousun Ko, Chi Hyuk Oh, Bo Hyun Kim, Seong Jin Park, Myung-Won You
Diagnostics.2022; 12(11): 2804. CrossRef - Low psoas muscle area is associated with postoperative complications in Crohn’s disease
Yaniv Zager, Saed Khalilieh, Omar Ganaiem, Eli Gorgov, Nir Horesh, Roi Anteby, Uri Kopylov, Harel Jacoby, Yael Dreznik, Assaf Dori, Mordechai Gutman, Avinoam Nevler
International Journal of Colorectal Disease.2021; 36(3): 543. CrossRef - Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease
Gurasis Boparai, Saurabh Kedia, Devasenathipathy Kandasamy, Raju Sharma, Kumble Seetharama Madhusudhan, Nihar Ranjan Dash, Pabitra Sahu, Sujoy Pal, Peush Sahni, Rajesh Panwar, Sudheer Kumar Vuyyuru, Bhaskar Kante, Davesh P. Yadav, Venigalla Pratap Mouli,
European Journal of Clinical Nutrition.2021; 75(10): 1491. CrossRef - Sarcopenia in Inflammatory Bowel Disease: A Narrative Overview
Amritpal Dhaliwal, Jonathan I. Quinlan, Kellie Overthrow, Carolyn Greig, Janet M. Lord, Matthew J. Armstrong, Sheldon C. Cooper
Nutrients.2021; 13(2): 656. CrossRef - Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together
Francesco Palmese, Rossella Del Toro, Giulia Di Marzio, Pierluigi Cataleta, Maria Giulia Sama, Marco Domenicali
Nutrients.2021; 13(4): 1378. CrossRef - Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease
Lewis Steell, Stuart R. Gray, Richard K. Russell, Jonathan MacDonald, John Paul Seenan, Sze Choong Wong, Daniel R. Gaya
Nutrients.2021; 13(8): 2899. CrossRef - Inflammatory Bowel Disease and Sarcopenia: Its Mechanism and Clinical Importance
Hiroki Nishikawa, Shiro Nakamura, Takako Miyazaki, Kazuki Kakimoto, Shinya Fukunishi, Akira Asai, Shuhei Nishiguchi, Kazuhide Higuchi
Journal of Clinical Medicine.2021; 10(18): 4214. CrossRef - Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications
Dorota Skrzypczak, Marzena Skrzypczak-Zielińska, Alicja Ewa Ratajczak, Aleksandra Szymczak-Tomczak, Piotr Eder, Ryszard Słomski, Agnieszka Dobrowolska, Iwona Krela-Kaźmierczak
Biomedicines.2021; 9(10): 1301. CrossRef - Adults with Crohn’s disease exhibit elevated gynoid fat and reduced android fat irrespective of disease relapse or remission
Lisa Dowling, Philip Jakeman, Catherine Norton, Maeve M. Skelly, Hamid Yousuf, Miranda G. Kiernan, Margaret Toomey, Sheila Bowers, Suzanne S. Dunne, J. Calvin Coffey, Colum P. Dunne
Scientific Reports.2021;[Epub] CrossRef - What Determines Good Rehabilitation Recovery in Stroke Patients with very Severe Disability? A Retrospective Cohort Study
Shengjie Zhao, Tong Zhang, Bingjie Li, Zhangwei Wu, Jun Zhao
Journal of Stroke and Cerebrovascular Diseases.2020; 29(10): 105130. CrossRef - Sarcopenia in Autoimmune and Rheumatic Diseases: A Comprehensive Review
Hyo Jin An, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Keum Hwa Lee, Seoung Wan Nam, Jae Seok Kim, Jae Won Yang, Jun Young Lee, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Jae Il Shin, Andreas Kronbichler
International Journal of Molecular Sciences.2020; 21(16): 5678. CrossRef - Diagnosis of malnutrition in patients with gastrointestinal diseases: recent observations from a Global Leadership Initiative on Malnutrition perspective
Tommy Cederholm, Zeljko Krznaric, Matthias Pirlich
Current Opinion in Clinical Nutrition & Metabolic Care.2020; 23(5): 361. CrossRef - Incorporating Frailty in the Treatment Program of Elderly Patients with Gastrointestinal Disease
C. Thompson, S. Taleban
Current Treatment Options in Gastroenterology.2020; 18(4): 635. CrossRef
- Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence
- 8,832 View
- 218 Download
- 40 Web of Science
- 42 Crossref
- Inflammatory bowel diseases
- 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
- Shinta Mizuno, Keiko Ono, Yohei Mikami, Makoto Naganuma, Tomohiro Fukuda, Kazuhiro Minami, Tatsuhiro Masaoka, Soichiro Terada, Takeshi Yoshida, Keiichiro Saigusa, Norimichi Hirahara, Hiroaki Miyata, Wataru Suda, Masahira Hattori, Takanori Kanai
- Intest Res 2020;18(1):69-78. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00084
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
5-Aminosalicylic acid (ASA) causes intolerance reactions in some patients. This study was performed to examine the prognosis of patients with ulcerative colitis (UC) and 5-ASA intolerance, and to evaluate the potential interaction between 5-ASA intolerance and the intestinal microbiota.
Methods
We performed a retrospective cohort study of patients with UC who visited participating hospitals. The primary endpoint was to compare the incidence of hospitalization within 12 months between the 5-ASA intolerance group and the 5-ASA tolerance group. The secondary endpoint was to compare the risk of adverse clinical outcomes after the start of biologics between the 2 groups. We also assessed the correlation between 5-ASA intolerance and microbial change in an independently recruited cohort of patients with UC.
Results
Of 793 patients, 59 (7.4%) were assigned to the 5-ASA intolerance group and 734 (92.5%) were assigned to the 5-ASA tolerance group. The admission rate and incidence of corticosteroid use were significantly higher in the intolerance than tolerance group (P< 0.001). In 108 patients undergoing treatment with anti-tumor necrosis factor biologics, 5-ASA intolerance increased the incidence of additional induction therapy after starting biologics (P< 0.001). The 5-ASA intolerance group had a greater abundance of bacteria in the genera Faecalibacterium, Streptococcus, and Clostridium than the 5-ASA tolerance group (P< 0.05).
Conclusions
In patients with UC, 5-ASA intolerance is associated with a risk of adverse clinical outcomes and dysbiosis. Bacterial therapeutic optimization of 5-ASA administration may be important for improving the prognosis of patients with UC. -
Citations
Citations to this article as recorded by- Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
Internal Medicine.2024; 63(8): 1081. CrossRef - The impact of 5-aminosalicylates on the efficacy of mesenchymal stem cell therapy in a murine model of ulcerative colitis
Huanhuan Chen, Huimin Wang, XiaoJing Xu, Ya'nan Hu, Jing Su, Dongdong Li, Zimu Li, Shixiang Feng, Jinming Liu, Huanxiang Zhang, Xiaoyan Wang
International Immunopharmacology.2024; 134: 112255. CrossRef - Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance
Hiroshi Matsumoto, Momoyo Sasahira, Tei Tei Go, Shogen Yo, Takehiro Ninomiya, Motoyasu Osawa, Osamu Handa, Eiji Umegami, Ryo Inoue, Akiko Shiotani
Biomedicines.2024; 12(9): 2125. CrossRef - Manipulating Microbiota in Inflammatory Bowel Disease Treatment: Clinical and Natural Product Interventions Explored
Mengjie Zhu, Yijie Song, Yu Xu, Hongxi Xu
International Journal of Molecular Sciences.2023; 24(13): 11004. CrossRef - Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
Pediatrics International.2023;[Epub] CrossRef - CURRENT STATUS, PROBLEMS AND PROSPECTS OF ULCERATIVE COLITIS MEDICAL CORRECTION (LITERATURE REVIEW)
T. O. Briukhanova, O. A. Nakonechna, O. V Babenko
Bulletin of Problems Biology and Medicine.2023; 1(3): 28. CrossRef - Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
Digestion.2023; 104(1): 58. CrossRef - Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
Inflammatory Bowel Diseases.2022; 28(1): 21. CrossRef - Classification and clinical features of adverse drug reactions in patients with ulcerative colitis treated with 5‐aminosalicylate acid: a single-center, observational study
Yuri Tsujii, Tsutomu Nishida, Naoto Osugi, Yoshifumi Fujii, Aya Sugimoto, Dai Nakamatsu, Kaori Mukai, Kengo Matsumoto, Shiro Hayashi, Masashi Yamamoto, Sachiko Nakajima
Scandinavian Journal of Gastroenterology.2022; 57(2): 190. CrossRef - The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
Eun Ae Kang
Gut and Liver.2022; 16(3): 487. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef - The emerging microbiome‐based approaches to IBD therapy: From SCFAs to urolithin A
Mohammad Rudiansyah, Saade Abdalkareem Jasim, Bakhadir S. Azizov, Vadim Samusenkov, Walid Kamal Abdelbasset, Ghulam Yasin, Hawraa Jabbar Mohammad, Mohammed Abed Jawad, Trias Mahmudiono, Seyed Reza Hosseini‐Fard, Rasoul Mirzaei, Sajad Karampoor
Journal of Digestive Diseases.2022; 23(8-9): 412. CrossRef - Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2021; 36(1): 137. CrossRef - Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis
Anas Ahmad, Md. Meraj Ansari, Rakesh Kumar Mishra, Ajay Kumar, Akshay Vyawahare, Rahul Kumar Verma, Syed Shadab Raza, Rehan Khan
Materials Science and Engineering: C.2021; 119: 111582. CrossRef - Bacteriotherapy for inflammatory bowel disease
Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
Inflammation and Regeneration.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies
Yu Hu, Zhen Ye, Mingquan Wu, Yingqi She, Linzhen Li, Yujie Xu, Kaihua Qin, Zhipeng Hu, Maoyi Yang, Fating Lu, Qiaobo Ye
Frontiers in Medicine.2021;[Epub] CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - 5‐aminosalicylate–intolerant patients are at increased risk of colectomy for ulcerative colitis
Shuji Hibiya, Yusuke Matsuyama, Toshimitsu Fujii, Chiaki Maeyashiki, Eiko Saito, Kimiko Ito, Hiromichi Shimizu, Ami Kawamoto, Maiko Motobayashi, Kento Takenaka, Masakazu Nagahori, Masayuki Kurosaki, Tsunehito Yauchi, Kazuo Ohtsuka, Takeo Fujiwara, Ryuichi
Alimentary Pharmacology & Therapeutics.2021; 53(1): 103. CrossRef - Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Satohiro Matsumoto, Hirosato Mashima
Scientific Reports.2020;[Epub] CrossRef
- Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
- 7,382 View
- 336 Download
- 23 Web of Science
- 21 Crossref
- Inflammatory bowel diseases
- Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
- Toshifumi Hibi, Makoto Naganuma, Eisei Oda, Yoji Yamada, Yoshitomo Chujoh, Ryoichi Yoshihara, Mamoru Watanabe
- Intest Res 2020;18(1):56-68. Published online December 11, 2019
- DOI: https://doi.org/10.5217/ir.2019.00064
-
Abstract
PDFPubReaderePub
- Background/Aims
Mucosal healing (MH) of distal lesions in ulcerative colitis (UC) has recently been confirmed with budesonide 2-mg foam (BF) treatment in 2 clinical trials; however, few studies have investigated the predictive factors for complete MH.
Methods
We conducted a post hoc analysis using pooled data from phase II and III clinical trials evaluating the efficacy and safety of BF for UC. Additionally, we analyzed the relationships between complete MH and baseline factors and clinical symptoms from baseline to week 6.
Results
Among the 291 Japanese patients from the 2 pooled clinical studies, 119 patients in the BF twice a day group and 117 in the placebo group were included in the full analysis set. The proportion of patients with a rectal bleeding (RB) subscore of 0 was significantly higher in the BF group than in the placebo group after a 5-day treatment (P<0.05). After a 2-day treatment, significantly more patients in the BF group had a stool frequency (SF) subscore of 0 than patients in the placebo group (P<0.05). Multivariate analysis showed that complete MH at week 6 was influenced by baseline SF subscore and 5-aminosalicylic acid (5-ASA) enema or suppository use (P=0.0086 and P=0.0015, respectively). The relationship between complete MH at week 6 and RB subscore after week 2 was also confirmed.
Conclusions
Normal SF at baseline, history of 5-ASA topical product use, and elimination of RB after week 2 are suggested predictors of complete MH at week 6 with twice-daily BF treatment. -
Citations
Citations to this article as recorded by- Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis
Kenji Watanabe, Fumihito Hirai, Kiyonori Kobayashi, Ken Takeuchi, Shinsuke Kurosu, Katsutoshi Inagaki, Ken‐ichi Iwayama, Makoto Naganuma
Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef - Precision medicine and drug optimization in adult inflammatory bowel disease patients
Sophie Vieujean, Edouard Louis
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef - The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
Eun Ae Kang
Gut and Liver.2022; 16(3): 487. CrossRef - Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study
Ryosuke Miyazaki, Toshiyuki Sakurai, Mariko Shimada, Yuko Iwashita, Naoki Shibuya, Yoshihiro Akita, Haruna Miyashita, Yuki Maruyama, Masayuki Saruta
BMC Gastroenterology.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef - Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone
Therapeutics and Clinical Risk Management.2021; Volume 17: 285. CrossRef
- Impact of twice‐daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis
- 5,823 View
- 179 Download
- 9 Web of Science
- 7 Crossref
- Inflammatory bowel diseases
- Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
- Masayuki Saruta, Dong Il Park, Young-Ho Kim, Suk-Kyun Yang, Byung-Ik Jang, Jae Hee Cheon, Jong Pil Im, Takanori Kanai, Tatsuro Katsuno, Yoh Ishiguro, Makoto Nagaoka, Naoki Isogawa, Yinhua Li, Anindita Banerjee, Alaa Ahmad, Mina Hassan-Zahraee, Robert Clare, Kenneth J. Gorelick, Fabio Cataldi, Mamoru Watanabe, Toshifumi Hibi
- Intest Res 2020;18(1):45-55. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00039
-
Abstract
PDFPubReaderePub
- Background/Aims
PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD).
Methods
OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients.
Results
In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7+ central memory CD4+ T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment.
Conclusions
In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509) -
Citations
Citations to this article as recorded by- Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef - Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef - Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
Maximilian Wiendl, Emily Becker, Tanja M. Müller, Caroline J. Voskens, Markus F. Neurath, Sebastian Zundler
Frontiers in Immunology.2021;[Epub] CrossRef - Renin–angiotensin system in intestinal inflammation—Angiotensin inhibitors to treat inflammatory bowel diseases?
Hanne Salmenkari, Riitta Korpela, Heikki Vapaatalo
Basic & Clinical Pharmacology & Toxicology.2021; 129(3): 161. CrossRef - Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents
Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese
Expert Opinion on Investigational Drugs.2021; 30(10): 1037. CrossRef - Emerging therapeutic options in inflammatory bowel disease
Jesus K Yamamoto-Furusho, Norma N Parra-Holguín
World Journal of Gastroenterology.2021; 27(48): 8242. CrossRef
- Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
- 15,552 View
- 188 Download
- 7 Web of Science
- 6 Crossref
Reviews
- Inflammatory bowel diseases
- Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
- Sang Hyoung Park, Jae Cheol Park, Milan Lukas, Martin Kolar, Edward V. Loftus, Jr
- Intest Res 2020;18(1):34-44. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.09147
-
Abstract
PDFPubReaderePub
- The inflammatory bowel diseases (IBD), which consist of Crohn’s disease and ulcerative colitis, are chronic, incurable immunemediated inflammatory disorders of the intestine. As IBD incidence continues to increase globally and its mortality is low, prevalent cases of IBD are rapidly increasing, thereby leading to a substantial increase in health care costs. Although the introduction of biologic agents for IBD management has revolutionized the armamentarium of IBD therapy, the high cost of this therapy is concerning. With the expirations of patents for existing biologic agents (originals), biosimilars with cheaper costs have been highlighted in the field of IBD. Despite concerns regarding their short- and long-term efficacy, safety, immunogenicity, and interchangeability, increasing evidence via prospective observations and phase III or IV clinical trials, which aim to prove the “biosimilarity” of biosimilars to originals, has partly confirmed their efficacy, safety, and interchangeability. Additionally, although patients and physicians are reluctant to use biosimilars, a positive budget impact has been reported owing to their use in different countries. In the near future, multiple biosimilars with lower costs, and efficacy and safety profile similar to originals, could be used to treat IBD; thus, further consideration and knowledge dissemination are warranted in this new era of biosimilars.
-
Citations
Citations to this article as recorded by- Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
Gut and Liver.2024; 18(3): 489. CrossRef - Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience
Thomas W. J. Huizinga, Valeria Dipasquale, Markus Zabransky, Jens Heyn, Claudio Romano
Expert Opinion on Biological Therapy.2024; 24(7): 615. CrossRef - Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
Journal of Clinical Gastroenterology.2023; 57(6): 601. CrossRef - Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim
Intestinal Research.2023; 21(1): 43. CrossRef - Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
Harpreet Singh, Liam Wilson, Tom Tencer, Jinender Kumar
ClinicoEconomics and Outcomes Research.2023; Volume 15: 125. CrossRef - PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison
Journal of Pediatric Gastroenterology & Nutrition.2023; 76(4): 451. CrossRef - Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
Gut and Liver.2023; 17(3): 430. CrossRef - Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals
Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque
Therapies.2022; 77(4): 467. CrossRef - A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Richard Kay, Halimu N. Haliduola, Fausto Berti
Expert Opinion on Investigational Drugs.2022; 31(9): 965. CrossRef - The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)
Enrique de-Madaria, José J Mira, Irene Carrillo, Waqqas Afif, Daphne Ang, Marina Antelo, Steven Bollipo, Antoni Castells, Prabhleen Chahal, Henriette Heinrich, Joanna K Law, Monique E van Leerdam, Sabela Lens, Rahul Pannala, San Hyoung Park, Atoosa Rabiee
The Lancet Gastroenterology & Hepatology.2022; 7(5): 485. CrossRef - Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
Jongwook Yu, Hye Kyung Hyun, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Gut and Liver.2022; 16(3): 414. CrossRef - Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian
Frontiers in Medicine.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor
Yaron Ilan
International Journal of Environmental Research and Public Health.2021; 18(2): 811. CrossRef - Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
Kyung‐Sang Yu, In‐Jin Jang, Hyeong‐Seok Lim, Jang Hee Hong, Min‐Gul Kim, Min Kyu Park, Doo‐Yeoun Cho, Min Soo Park, Jae Yong Chung, Jong‐Lyul Ghim, SeungHwan Lee, Seok Kyu Yoon, In Sun Kwon, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Jung Bin Cha, Daniel E
Clinical and Translational Science.2021; 14(4): 1280. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef - Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
Karen Hanson
Crohn's & Colitis 360.2021;[Epub] CrossRef - Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
Anna Pękala, Rafał Filip
Journal of Clinical Medicine.2021; 10(22): 5311. CrossRef
- Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
- 6,796 View
- 210 Download
- 20 Web of Science
- 19 Crossref
- Inflammatory bowel diseases
- Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases
- Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen, IBD Research Group of the Korean Association for the Study of Intestinal Diseases
- Intest Res 2020;18(1):18-33. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.09155
-
Abstract
PDFPubReaderePub
- The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.
-
Citations
Citations to this article as recorded by- Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
Middle East Journal of Digestive Diseases.2023; 15(2): 83. CrossRef - Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review
Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian
Archives of Microbiology.2023;[Epub] CrossRef - The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
Frontiers in Pharmacology.2023;[Epub] CrossRef - SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
Intestinal Research.2022; 20(2): 171. CrossRef - Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi
Gut and Liver.2022; 16(3): 396. CrossRef - Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
Eun Ae Kang, Jae Hee Cheon
Gut and Liver.2022; 16(4): 501. CrossRef - Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
Gut and Liver.2022; 16(4): 567. CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef - Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef - Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian
Gut and Liver.2022; 16(5): 726. CrossRef - Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
Suhyun Park, Sang Hyoung Park
Gut and Liver.2022; 16(5): 663. CrossRef - Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef - Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach
Vlad Alexandru Ionescu, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu
Gastroenterology Insights.2022; 14(1): 13. CrossRef - Viral infections in inflammatory bowel disease: Tips and tricks for correct management
Vincenzo Craviotto, Federica Furfaro, Laura Loy, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese, Mariangela Allocca
World Journal of Gastroenterology.2021; 27(27): 4276. CrossRef - SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 117. CrossRef - Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef - A clinical case of ulcerative colitis in a patient with viral hepatitis
E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
South Russian Journal of Therapeutic Practice.2020; 1(3): 95. CrossRef
- Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
- 8,164 View
- 280 Download
- 15 Web of Science
- 18 Crossref
- Inflammatory bowel diseases
- Pediatric to adult inflammatory bowel disease transition: the Asian experience
- Bernice Tan, David Ong
- Intest Res 2020;18(1):11-17. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.09144
-
Abstract
PDFPubReaderePub
- Many tertiary inflammatory bowel disease (IBD) centers recognize that a structured transition program is fundamental for an IBD unit. However, the path to ensuring a seamless transition for all stakeholders is often fraught with challenges. In this review, we go through current evidence, identify the requirementsof a successful transition program, and the barriers to seamless transfer. We also aim to shed light on differences in needs between the Western and Asian adolescent IBD populations. Majority of healthcare providers viewed having a structured transition program to be very important. The lack of a standard protocol led us to come up with a list of requirements ofa successful program. These include: multidisciplinary team meetings, alternating visits between the adultand pediatric clinics, proper documentation of records, and determining the ideal timing for transfer. The difficulties forthe Asian adolescent IBD population may be attributed to the reliance on parental support to make decisions regarding medicaltreatment. Lastly, there are various physician, patient and disease factors which are barriers to seamless transition. These includethe lack of proper documentation, and lack of patient self-efficacy. We also propose a standardized template for documentation of medical records for IBD patients.
-
Citations
Citations to this article as recorded by- Systematic Review: Practices and Programs in Inflammatory Bowel Disease Transition Care
Patrick Chan, Jack McNamara, Angharad Vernon-Roberts, Edward M Giles, Rachael Havrlant, Britt Christensen, Amanda Thomas, Astrid-Jane Williams
Inflammatory Bowel Diseases.2024;[Epub] CrossRef - Current perspectives on pediatric inflammatory bowel disease focusing on transitional care management. What should we consider?
Constanza Bay M, Paulina Núñez F, Rodrigo Quera, Andrés J. Yarur
Gastroenterología y Hepatología.2023; 46(2): 139. CrossRef - Current perspectives on pediatric inflammatory bowel disease focusing on transitional care management. What should we consider?
Constanza Bay M, Paulina Núñez F, Rodrigo Quera, Andrés J. Yarur
Gastroenterología y Hepatología (English Edition).2023; 46(2): 139. CrossRef - Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(9): 541. CrossRef - Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
Journal of Crohn's and Colitis.2022; 16(2): 207. CrossRef - A consensus statement on health‐care transition for childhood‐onset inflammatory bowel disease patients
Hideki Kumagai, Toshiaki Shimizu, Itaru Iwama, Shin‐Ichiro Hagiwara, Takahiro Kudo, Michiko Takahashi, Takeshi Saito, Reiko Kunisaki, Motoi Uchino, Sakiko Hiraoka, Makoto Naganuma, Ken Sugimoto, Jun Miyoshi, Tomoyoshi Shibuya, Tadakazu Hisamatsu
Pediatrics International.2022;[Epub] CrossRef - Vaccination strategies for Korean patients with inflammatory bowel disease
Yoo Jin Lee, Eun Soo Kim
The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef - Transition of adult patients with pediatric orthostatic intolerance from child-centered care to adult-centered care
Yoshitoki Yanagimoto
Frontiers in Pediatrics.2022;[Epub] CrossRef - Transitional care for inflammatory bowel disease: A survey of Japanese pediatric gastroenterologists
Hideki Kumagai, Takahiro Kudo, Keiichi Uchida, Reiko Kunisaki, Akira Sugita, Yoshikazu Ohtsuka, Katsuhiro Arai, Mitsuru Kubota, Hitoshi Tajiri, Yasuo Suzuki, Toshiaki Shimizu
Pediatrics International.2021; 63(1): 65. CrossRef - The Coming-of-Age Transition Care for Adolescents with Rheumatic Disease—Where Are We and What Have We Done in Asia?
Kai Liang Teh, Sook Fun Hoh, Thaschawee Arkachaisri
Journal of Clinical Medicine.2021; 10(4): 821. CrossRef - How Can We Do Transition Successfully from Pediatric to Adult Clinics in Inflammatory Bowel Disease?
Mi Jin Kim, Sung Noh Hong, Young-Ho Kim, Yon Ho Choe
The Korean Journal of Gastroenterology.2021; 77(5): 227. CrossRef - Transition Services for Pediatric Inflammatory Bowel Disease: Ready for Asian Patients Yet?
Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
Journal of Pediatric Gastroenterology & Nutrition.2021; 73(4): e107. CrossRef - Transitional Care for Patients with Inflammatory Bowel Disease: Japanese Experience
Hideki Kumagai, Yasuo Suzuki, Toshiaki Shimizu
Digestion.2021; 102(1): 18. CrossRef
- Systematic Review: Practices and Programs in Inflammatory Bowel Disease Transition Care
- 4,848 View
- 146 Download
- 13 Web of Science
- 13 Crossref
- Inflammatory bowel diseases
- Update of endoscopic management of Crohn’s disease strictures
- Akshay Pokala, Bo Shen
- Intest Res 2020;18(1):1-10. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.09158
-
Abstract
PDFPubReaderePub
- One of the most common complications of Crohn’s disease (CD) is the formation of strictures. Endoscopy plays a vital role not only in the diagnosis, differential diagnosis, and disease monitoring of CD, but also the delivery of effective treatment. The purpose of this review is to update the endoscopic management of strictures in CD. Endoscopic therapy has provided minimally invasive treatment for CD. Commonly used endoscopic treatment modalities include balloon dilation, endoscopic stricturotomy, endoscopic strictureplasty, and endoscopic stenting. The pros and cons of these endoscopic treatment modalities are discussed.
-
Citations
Citations to this article as recorded by- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era
Kush Fansiwala, Ellen J Spartz, Andrew R Roney, Mary R Kwaan, Jenny S Sauk, Po-Hung Chen, Berkeley N Limketkai
Inflammatory Bowel Diseases.2024;[Epub] CrossRef - Clinical outcomes of serial endoscopic balloon dilation for duodenal Crohn’s disease-associated strictures
Juanjuan Zhang, Xiaoli Qian, Lin Zhu, Binlin Da, Xiaofan Zhao, Qin He, Lixin Wang, Yi Li, Zhiming Wang
Surgical Endoscopy.2024; 38(8): 4512. CrossRef - Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case
Gaetano Coppola, Chiara Principessa, Federica Di Vincenzo, Pierluigi Puca, Angelo Del Gaudio, Ivan Capobianco, Bianca Bartocci, Alfredo Papa, Giovanni Cammarota, Loris Riccardo Lopetuso, Franco Scaldaferri
Journal of Clinical Medicine.2024; 13(16): 4842. CrossRef - The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms
Iona Campbell, Michael Glinka, Fadlo Shaban, Kathryn J. Kirkwood, Francesca Nadalin, David Adams, Irene Papatheodorou, Albert Burger, Richard A. Baldock, Mark J. Arends, Shahida Din
Journal of Clinical Medicine.2023; 12(12): 3884. CrossRef - How to Prevent and Treat the Most Frequent Adverse Events Related to Luminal Dilation and Stenting in Benign Disease
Eduardo Rodrigues-Pinto, Joel Ferreira-Silva, Peter D. Siersema
American Journal of Gastroenterology.2023; 118(9): 1521. CrossRef - Crohn's disease: an update
Ella Cockburn, Shahed Kamal, Andrea Chan, Vikram Rao, Tianwei Liu, Joanna Y Huang, Jonathan P Segal
Clinical Medicine.2023; 23(6): 549. CrossRef - Documento de posicionamiento. Recomendaciones del grupo español de trabajo en enfermedad de Crohn y colitis ulcerosa (GETECCU) sobre el tratamiento de la estenosis en la enfermedad de Crohn
Carme Loras, Miriam Mañosa, Xavier Andújar, Vicente Sánchiz, Marc Martí-Gallostra, Yamile Zabana, Ana Gutiérrez, Manuel Barreiro-de Acosta
Gastroenterología y Hepatología.2022; 45(4): 315. CrossRef - Endoscopic Balloon Dilation Is Cost-Effective for Crohn’s Disease Strictures
Kate E. Lee, Francesca Lim, Adam S. Faye, Bo Shen, Chin Hur
Digestive Diseases and Sciences.2022; 67(12): 5462. CrossRef - Position Statement. Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU) on the treatment of strictures in Crohn’s disease
Carme Loras, Miriam Mañosa, Xavier Andújar, Vicente Sánchiz, Marc Martí-Gallostra, Yamile Zabana, Ana Gutiérrez, Manuel Barreiro-de Acosta
Gastroenterología y Hepatología (English Edition).2022; 45(4): 315. CrossRef - Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice
Kyeong Ok Kim
Clinical Endoscopy.2022; 55(4): 480. CrossRef - Esophageal Manifestations of Dermatological Diseases, Diagnosis, and Management
Amr M. Arar, Kelli DeLay, David A. Leiman, Paul Menard-Katcher
Current Treatment Options in Gastroenterology.2022; 20(4): 513. CrossRef - Active Assessment of Inflammatory Bowel Disease
金良 肖
Advances in Clinical Medicine.2022; 12(12): 11023. CrossRef - Long-Term Outcome of Endoscopic Balloon Dilation for Duodenal Crohn’s Disease-Associated Strictures
Juanjuan Zhang, Yi Li, Yanqing Diao, Binlin Da, Zhiming Wang
Digestive Diseases and Sciences.2021; 66(10): 3570. CrossRef - Story of strictures, stents, and many more
Saiprasad Girish Lad, Kailash M. Kolhe, Shamshersingh G. Chauhan, Meghraj A. Ingle, Mayur Gattani, Harshad Khairnar
Gastrointestinal Endoscopy.2021; 93(2): 535. CrossRef - Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef - Managing Stricturing Crohn's Disease: Resect? Strictureplasty? Dilate?
Lea Lowenfeld, Fabrizio Michelassi
Journal of Laparoendoscopic & Advanced Surgical Techniques.2021; 31(8): 881. CrossRef - Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
- Increasing Rates of Bowel Resection Surgery for Stricturing Crohn’s Disease in the Biologic Era
- 8,218 View
- 273 Download
- 14 Web of Science
- 17 Crossref
Images of the Issue
- IBD
- Stroke and neck bruit in a boy with Crohn’s disease
- Ryosaku Tomiyama, Akira Hokama, Erika Koga, Kohei Shimabukuro, Yuiko Oishi, Tetsuya Ohira, Atsushi Iraha, Tetsu Kinjo, Jiro Fujita
- Intest Res 2019;17(4):565-566. Published online April 15, 2019
- DOI: https://doi.org/10.5217/ir.2019.00019
- 5,385 View
- 111 Download
Case Report
- Colorectal neoplasia
- Primary malignant melanoma without melanosis of the colon
- Nam Hee Yi, Sang Heon Lee, Sang Heon Lee, Ji Hyun Kim, Sam Ryong Jee, Sang Yong Seol
- Intest Res 2019;17(4):561-564. Published online August 5, 2019
- DOI: https://doi.org/10.5217/ir.2019.00020
-
Abstract
PDFPubReaderePub
- Primary malignant melanoma (PMM) of the gastrointestinal tract is rare. Reported cases of PMM of the lower gastrointestinal tract typically describe anal and rectal involvement rather than colonic lesions. This report describes a rare case of a 50-year-old woman with PMM originating in the colon. The patient presented to Inje University Busan Paik Hospital with a 3-day history of blood-tinged stools. She underwent colonoscopy for a diagnosis of hematochezia. The colonoscopic examination revealed a large-sized semi-pedunculated sigmoid colon polyp with a reddish-colored mucosal surface. Endoscopic mucosal resection was performed, and the final histopathological findings were consistent with a diagnosis of malignant melanoma. Systemic work-up was performed for assessment of metastasis and to identify the primary tumor considering the high metastatic rate of gastrointestinal malignant melanoma; however, no other malignant lesion was detected. Thus, she was diagnosed with colonic PMM. She underwent laparoscopic low anterior resection and lymph node dissection and has been recurrence-free for > 2 years.
-
Citations
Citations to this article as recorded by- Malignant primary melanoma of the colon: a case report
Claire K Foley, Marybeth S Hughes, Charles T Hehman
Journal of Surgical Case Reports.2023;[Epub] CrossRef
- Malignant primary melanoma of the colon: a case report
- 6,216 View
- 180 Download
- 4 Web of Science
- 1 Crossref
Original Articles
- Miscellaneous
- Primary epiploic appendagitis: compared with diverticulitis and focused on obesity and recurrence
- Youn I Choi, Hyun Sun Woo, Jun-Won Chung, Young Sup Shim, Kwang An Kwon, Kyoung Oh Kim, Yoon Jae Kim, Dong Kyun Park
- Intest Res 2019;17(4):554-560. Published online October 14, 2019
- DOI: https://doi.org/10.5217/ir.2018.00148
-
Abstract
PDFPubReaderePub
- Background/Aims
There is limited data to compare the clinical characteristics and recurrence rates between left-sided primary epiploic appendagitis (PEA) versus left-sided acute colonic diverticulitis (ACD), and right-sided PEA versus right-sided ACD, respectively.
Methods
We retrospectively reviewed the medical records and radiologic images of the patients who presented with left-sided or right-sided acute abdominal pain and had computer tomography performed at the time of presentation showing radiological signs of PEA or ACD between January 2004 and December 2014. We compared the clinical characteristics of left PEA versus left ACD and right PEA versus right ACD, respectively.
Results
Fifty-six patients (left:right = 27:29) and 308 patients (left:right = 24:284) were diagnosed with symptomatic PEA and ACD, respectively. Left-sided PEA were statistically significantly younger (50.2 ± 15.4 years vs. 62.1 ± 15.8 years, P= 0.009), more obese (body mass index [BMI]: 26.3 ± 2.9 kg/m2 vs. 22.3 ± 3.1 kg/m2 , P< 0.001), and had more tendencies with normal or mildly elevated high-sensitivity C-reactive protein (hsCRP) (1.2 ± 1.3 mg/dL vs. 8.4 ± 7.9 mg/dL, P< 0.001) than patients with left-sided ACD. The discriminative function of age, BMI and CRP between left-sided PEA versus left-sided ACD was 0.71 (cutoff: age ≤ 59 years, sensitivity of 66.7%, specificity of 77.8%), 0.83 (cutoff: BMI > 24.5 kg/m2 , sensitivity of 80.0%, specificity of 80.0%) and 0.80 (cutoff: CRP < 1.8 mg/dL, sensitivity of 72.2%, specificity of 85.7%).
Conclusions
If patients with left lower quadrant abdominal pain are less than 60 years, obese (BMI > 24.5 kg/m2 ) with or without normal to mild elevated CRP levels (CRP < 1.8 mg/dL), it might be necessary for clinicians to suspect the diagnosis of PEA rather than ACD. -
Citations
Citations to this article as recorded by- Diagnosis and treatment of epiploic appendagitis in a Middle Eastern country: An observational retrospective analysis of 156 cases
Ayman El‐Menyar, Syed G. A. Naqvi, Omer Al‐Yahri, Abdelaziz MA Abusal, Abdulwahhab Al‐Shaikhli, Sadia Sajid, Husham Abdelrahman, Ahmad G. Kloub, Muhamed Ibnas, Rifat Latifi, Yasser M. R. Toble, Hassan Al‐Thani
World Journal of Surgery.2024; 48(6): 1363. CrossRef - Epiploic Adipose Tissue (EPAT) in Obese Individuals Promotes Colonic Tumorigenesis: A Novel Model for EPAT-Dependent Colorectal Cancer Progression
Rida Iftikhar, Patricia Snarski, Angelle N. King, Jenisha Ghimire, Emmanuelle Ruiz, Frank Lau, Suzana D. Savkovic
Cancers.2023; 15(3): 977. CrossRef - Recurrencia en pacientes con apendagitis epiploica: un reporte de caso
Mía Alejandra Gómez Corrales, Fabian Andrés Chávez Ecos, Jackeline Alexandra Espinoza Utani, Carlos Alberto Dávila Hernández
Revista colombiana de Gastroenterología.2023; 38(1): 94. CrossRef
- Diagnosis and treatment of epiploic appendagitis in a Middle Eastern country: An observational retrospective analysis of 156 cases
- 7,625 View
- 121 Download
- 2 Web of Science
- 3 Crossref
- Functional bowel disorders
- Is fecal calprotectin always normal in children with irritable bowel syndrome?
- You Jin Choi, Su Jin Jeong
- Intest Res 2019;17(4):546-553. Published online September 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00009
-
Abstract
PDFPubReaderePub
- Background/Aims
Fecal calprotectin (FC) is a marker of intraluminal intestinal inflammation. Intestinal inflammation may contribute to the pathophysiology of irritable bowel syndrome (IBS). This study evaluated FC levels in children with IBS and differences in FC levels in children stratified by IBS subtype and healthy controls (HCs).
Methods
A total of 157 children with IBS and 56 HCs aged 4–16 years (119 boys, 94 girls, mean age of 9.48 years) were included in this prospective study. Children with IBS were diagnosed using the Rome III criteria and classified into 4 subtypes: IBS with constipation (IBS-C, n=37), IBS with diarrhea (IBS-D, n=54), IBS with alternating constipation and diarrhea (IBS-M, n=49), and IBS unsubtyped (IBS-U, n=17); postinfectious IBS (PI-IBS) was also considered. The FC concentration in stool samples was analyzed using an enzyme-linked immunosorbent assay. All participants answered a questionnaire regarding several demographic and clinical characteristics.
Results
Children with IBS had significantly higher levels of FC than the HCs (88.71 μg/g vs. 17.77 μg/g). Among the 4 IBS subtypes, the FC concentration was highest in children with IBS-D, followed by those with IBS-M, IBS-C, and IBS-U (169.94 μg/g vs. 45.04, 31.22, and 33.52 μg/g, respectively), and these differences were statistically significant. For PI-IBS, 90% of cases were in the IBS-D group.
Conclusions
The FC level was significantly higher in children with IBS than in HCs and differed depending on the IBS subtype, supporting the notion that IBS is a type of low-grade bowel inflammation. -
Citations
Citations to this article as recorded by- Markers of Intestinal Permeability and Inflammation in Enterally Fed Children with Cerebral Palsy
Dorota Mickiewicz-Góra, Katarzyna Sznurkowska, Karolina Skonieczna-Żydecka, Arleta Drozd, Anna Borkowska, Maciej Zagierski, Joanna Troch, Agnieszka Szlagatys-Sidorkiewicz
Nutrients.2024; 16(15): 2447. CrossRef - Role of inflammation in pediatric irritable bowel syndrome
Giovanni Di Nardo, Cesare Cremon, Annamaria Staiano, Vincenzo Stanghellini, Osvaldo Borrelli, Caterina Strisciuglio, Claudio Romano, Saverio Mallardo, Elena Scarpato, Giovanni Marasco, Silvia Salvatore, Letizia Zenzeri, Enrico Felici, Licia Pensabene, Sim
Neurogastroenterology & Motility.2023;[Epub] CrossRef - The Role of Bovine Kappa-Casein Glycomacropeptide in Modulating the Microbiome and Inflammatory Responses of Irritable Bowel Syndrome
Yunyao Qu, Si Hong Park, David C. Dallas
Nutrients.2023; 15(18): 3991. CrossRef - Evaluating the Potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A Pilot Study
Yunyao Qu, Si Hong Park, David C. Dallas
Nutrients.2023; 15(19): 4174. CrossRef - Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome
Jun Hwan Kim, Dae Yong Yi, Yoo Min Lee, You Jin Choi, Ju Young Kim, Yong Hee Hong, Ji Young Park, Su Yeong Kim, Na Mi Lee, Sin Weon Yun, Soo Ahn Chae, In Seok Lim, Eung Sang Choi, In Sook Jeong
Medicine.2022; 101(32): e29968. CrossRef - Infantile Colic and the Subsequent Development of the Irritable Bowel Syndrome
Ju Hee Kim, Seung Won Lee, Yoowon Kwon, Eun Kyo Ha, Jaewoo An, Hye Ryeong Cha, Su Jin Jeong, Man Yong Han
Journal of Neurogastroenterology and Motility.2022; 28(4): 618. CrossRef - Irritable bowel syndrome in Indonesian adolescents
Yudianita Kesuma, Rini Sekartini, Ina S. Timan, Agnes Kurniawan, Saptawati Bardosono, Agus Firmansyah, Yvan Vandenplas
Jornal de Pediatria.2021; 97(2): 197. CrossRef - An Update on the Assessment and Management of Pediatric Abdominal Pain
Craig Friesen, Jennifer M Colombo, Amanda Deacy, Jennifer V Schurman
Pediatric Health, Medicine and Therapeutics.2021; Volume 12: 373. CrossRef - Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis
Caterina Carco, Wayne Young, Richard B. Gearry, Nicholas J. Talley, Warren C. McNabb, Nicole C. Roy
Frontiers in Cellular and Infection Microbiology.2020;[Epub] CrossRef
- Markers of Intestinal Permeability and Inflammation in Enterally Fed Children with Cerebral Palsy
- 9,745 View
- 165 Download
- 9 Web of Science
- 9 Crossref
- Functional bowel disorders
- Frequency and intensity of gastrointestinal symptoms in exercisers individuals at rest and during physical exercise: an internet-based survey
- Claudio Andre Barbosa de Lira, Ricardo Borges Viana, Kaylla Priscilla Mesquista, Douglas de Assis Teles Santos, Mário Hebling Campos, Marília Santos Andrade, Rodrigo Luiz Vancini
- Intest Res 2019;17(4):537-545. Published online May 7, 2019
- DOI: https://doi.org/10.5217/ir.2018.00162
-
Abstract
PDFPubReaderePub
- Background/Aims
Despite the evidence of a modest to high prevalence of gastrointestinal (GI) symptoms in recreational runners and endurance athletes, the frequency and intensity of GI symptoms in exercisers, but nonathletes, individuals from different modalities have been less investigated. Therefore, the present study aimed to assess the prevalence of GI symptoms in individuals that practice moderate or vigorous physical exercise, at rest and during physical exercise training session.
Methods
The sample consisted of 142 exercisers individuals (64 women and 78 men with mean age of 32.9 ± 10.7 years). Out of the 142 participants, 71 reported to perform moderate physical exercise and 71 reported to perform vigorous physical exercise. Participants were assessed by an internet-based questionnaire designed to assess the frequency and intensity (at rest and during physical exercise training session) of 18 GI symptoms.
Results
The GI symptoms most frequently reported by the respondents (during rest and physical exercise training session, respectively) were flatulence (90.8% and 69.7%), abdominal noise (77.5% and 41.5%), and eructation (73.9% and 52.1%). Overall, the frequency and intensity of symptoms were higher (P< 0.050) during rest than physical exercise training session for who perform moderate and vigorous physical exercise.
Conclusions
It can be concluded that GI symptoms in exercisers, but nonathletes, individuals are more prevalent during rest than during physical exercise training session, suggesting that moderate and vigorous physical exercise may act as a regulator of the GI tract. -
Citations
Citations to this article as recorded by- The Frequency and Severity of Gastrointestinal Symptoms in Rugby
Players
Sarah Chantler, Ruth Wood-Martin, Adrian Holliday, Glen Davison, Daniel R. Crabtree, Clint Readhead, Ben Jones
International Journal of Sports Medicine.2024; 45(04): 323. CrossRef - Exercise-Induced Gastrointestinal Symptoms in Endurance Sports: A Review of Pathophysiology, Symptoms, and Nutritional Management
Emanuela Ribichini, Giulia Scalese, Alessandra Cesarini, Chiara Mocci, Nadia Pallotta, Carola Severi, Enrico Stefano Corazziari
Dietetics.2023; 2(3): 289. CrossRef - Comparison of physiological and psychobiological acute responses between high intensity functional training and high intensity continuous training
Douglas A.T. Santos, Naiane S. Morais, Ricardo B. Viana, Gustavo C.T. Costa, Marilia S. Andrade, Rodrigo L. Vancini, Katja Weiss, Beat Knechtle, Claudio A.B. de Lira
Sports Medicine and Health Science.2023;[Epub] CrossRef
- The Frequency and Severity of Gastrointestinal Symptoms in Rugby
Players
- 7,614 View
- 163 Download
- 1 Web of Science
- 3 Crossref
- Colorectal neoplasia
- Parthenolide inhibits transforming growth factor β1-induced epithelial-mesenchymal transition in colorectal cancer cells
- Shi Mao Zhu, Yong Ran Park, Seung Yong Seo, In Hee Kim, Soo Teik Lee, Sang Wook Kim
- Intest Res 2019;17(4):527-536. Published online August 23, 2019
- DOI: https://doi.org/10.5217/ir.2019.00031
-
Abstract
PDFPubReaderePub
- Background/Aims
Transforming growth factor-β1 (TGF-β1) induction of epithelial-mesenchymal transition (EMT) is one of the mechanisms by which colorectal cancer (CRC) cells acquire migratory and invasive capacities, and subsequently metastasize. Parthenolide (PT) expresses multiple anti-cancer and anti-inflammatory activities that inhibit nuclear factor κB by targeting the IκB kinase complex. In the present study, we aimed to investigate whether PT can inhibit TGF-β1-induced EMT in CRC cell lines.
Methods
HT-29 and SW480 cell lines were used in the experiment. Cell viability was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and sub-G1 analysis was measured by flow cytometry. The induction of EMT by TGF-β1 and inhibition of the process by PT was analyzed by phase contrast microscopy, wounding healing, cellular migration and invasion assays, and Western blotting.
Results
TGF-β1 inhibits HT-29 cell proliferation, but has no effect on SW480 cell proliferation; different concentrations of TGF-β1 did not induce apoptosis in HT-29 and SW480 cells. PT attenuates TGF-β1-induced elongated, fibroblast-like shape changing in cells. PT inhibits TGF-β1-induced cell migration and cell invasion. In addition, other EMT markers such as β-catenin, Vimentin, Snail, and Slug were suppressed by PT, while E-cadherin was increased by PT.
Conclusions
Our findings show that PT inhibits TGF-β1-induced EMT by suppressing the expression of the mesenchymal protein and increasing expression of the epithelial protein. These findings suggest a novel approach for CRC treatment by suppression of TGF-β1-induced EMT. -
Citations
Citations to this article as recorded by- Cumin (Cuminum cyminum L.) seeds accelerates wound healing in rats: Possible molecular mechanisms
Khaled Abdul‐Aziz Ahmed, Ahmed A. J. Jabbar, Yaseen Galali, Ayman M. Al‐Qaaneh, Gökhan Akçakavak, Nur Ain Salehen, Rawaz Rizgar Hassan, Ramzi A. Mothana, Mahmood Ameen Abdulla, Omer I. Fantoukh, Sidig Hasson, Mohammed F. Hawwal
Skin Research and Technology.2024;[Epub] CrossRef - TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance
Allan M. Johansen, Steven D. Forsythe, Callum T. McGrath, Grayson Barker, Hugo Jimenez, Ravi K. Paluri, Boris C. Pasche
Clinical Cancer Research.2024; 30(17): 3676. CrossRef - Bitter taste signaling in cancer
Ana R. Costa, Ana C. Duarte, Ana R. Costa-Brito, Isabel Gonçalves, Cecília R.A. Santos
Life Sciences.2023; 315: 121363. CrossRef - Parthenolide inhibits proliferation and invasion, promotes apoptosis, and reverts the cell–cell adhesion loss through downregulation of NF‐κB pathway TNF‐α‐activated in colorectal cancer cells
Adriana S. Gehren, Waldemir F. de Souza, Annie C. M. Sousa‐Squiavinato, Diego A. A. Ramos, Bruno R. B. Pires, Eliana S. F. W. Abdelhay, Jose A. Morgado‐Diaz
Cell Biology International.2023; 47(9): 1638. CrossRef - Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition
Soad L. Kabil, Hayam E. Rashed, Noura Mostafa Mohamed, Nisreen E. Elwany
Life Sciences.2023; 331: 122037. CrossRef - TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer
Sumeet Singh, Vinita Gouri, Mukesh Samant
Medical Oncology.2023;[Epub] CrossRef - The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy
Tao An, Huanhuan Yin, Yanting Lu, Feng Liu
Drug Design, Development and Therapy.2022; Volume 16: 1255. CrossRef - Parthenolide reverses the epithelial to mesenchymal transition process in breast cancer by targeting TGFbeta1: In vitro and in silico studies
Hazera Binte Sufian, Julianna Maria Santos, Zeina S. Khan, Sobia Ahsan Halim, Ajmal Khan, Maliha Tabassum Munir, MD Khurshidul Zahid, Ahmed Al-Harrasi, Lauren S. Gollahon, Fazle Hussain, Shaikh Mizanoor Rahman
Life Sciences.2022; 301: 120610. CrossRef - Cinnamomum bejolghota Extract Inhibits Colorectal Cancer Cell Metastasis and TGF-β1-Induced Epithelial-Mesenchymal Transition via Smad and Non-Smad Signaling Pathway
Athicha Kittiwattanokhun, Sukanda Innajak, Etsu Tashiro, Masaya Imoto, Ramida Watanapokasin
Scientia Pharmaceutica.2022; 90(2): 30. CrossRef - Autoimmunity and Cancer—Two Sides of the Same Coin
Justyna Sakowska, Łukasz Arcimowicz, Martyna Jankowiak, Ines Papak, Aleksandra Markiewicz, Katarzyna Dziubek, Małgorzata Kurkowiak, Sachin Kote, Karolina Kaźmierczak-Siedlecka, Karol Połom, Natalia Marek-Trzonkowska, Piotr Trzonkowski
Frontiers in Immunology.2022;[Epub] CrossRef - Sesquiterpene Lactones and Cancer: New Insight into Antitumor and Anti-inflammatory Effects of Parthenolide-Derived Dimethylaminomicheliolide and Micheliolide
Yubo Dong, Xuanjin Qian, Jian Li, Ahmed Faeq Hussein
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef - Plants as a Source of Anticancer Agents: From Bench to Bedside
Wamidh H. Talib, Safa Daoud, Asma Ismail Mahmod, Reem Ali Hamed, Dima Awajan, Sara Feras Abuarab, Lena Hisham Odeh, Samar Khater, Lina T. Al Kury
Molecules.2022; 27(15): 4818. CrossRef - Pharmacological Targeting of Epithelial-to-Mesenchymal Transition in Colorectal Cancer
Nima Zafari, Mahla Velayati, Mohammadreza Nassiri, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A. Ferns, Amir Avan
Current Pharmaceutical Design.2022; 28(28): 2298. CrossRef - The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities
Rubén Varela‐Calviño, Marta Rodríguez‐Quiroga, Patrícia Dias Carvalho, Flavia Martins, André Serra‐Roma, Lorena Vázquez‐Iglesias, María Páez de la Cadena, Sérgia Velho, Oscar J. Cordero
IUBMB Life.2021; 73(5): 761. CrossRef Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF
Bo Tian, Yuhang Xiao, Junliang Ma, Wei Ou, Hui Wang, Jie Wu, Jinming Tang, Baihua Zhang, Xiaojuan Liao, Desong Yang, Zhining Wu, Xu Li, Yong Zhou, Min Su, Wenxiang Wang
OncoTargets and Therapy.2020; Volume 13: 7447. CrossRef- Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity
Alex S. Quy, Xingjian Li, Louise Male, Tatjana Stankovic, Angelo Agathanggelou, John S. Fossey
Tetrahedron.2020; : 131631. CrossRef - Reversal of Epithelial–Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids
Chang Hoon Lee
Cancers.2019; 11(12): 1841. CrossRef
- Cumin (Cuminum cyminum L.) seeds accelerates wound healing in rats: Possible molecular mechanisms
- 8,559 View
- 184 Download
- 19 Web of Science
- 17 Crossref
- Colorectal neoplasia
- Clinical outcomes of positive resection margin after endoscopic mucosal resection of early colon cancers
- Junseok Park, Hyun Gun Kim, Shin Ok Jeong, Hoon gil Jo, Hyo Yeop Song, Jeeyeon Kim, Seri Ryu, Youngyun Cho, Hyun Jin Youn, Seong Ran Jeon, Jin-Oh Kim, Bong Min Ko, Yoon Mi Jeen, So-Young Jin
- Intest Res 2019;17(4):516-526. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2018.00169
-
Abstract
PDFPubReaderePub
- Background/Aims
When determining the subsequent management after endoscopic resection of the early colon cancer (ECC), various factors including the margin status should be considered. This study assessed the subsequent management and outcomes of ECCs according to margin status.
Methods
We examined the data of 223 ECCs treated by endoscopic mucosal resection (EMR) from 215 patients during 2004 to 2014, and all patients were followed-up at least for 2 years.
Results
According to histological analyses, the margin statuses of all lesions after EMR were as follows: 138 cases (61.9%) were negative, 65 cases (29.1%) were positive for dysplastic cells on the resection margins, and 20 cases (8.9%) were uncertain. The decision regarding subsequent management was affected not only by pathologic outcomes but also by the endoscopist’s opinion on whether complete resection was obtained. Surgery was preferred if the lesion extended to the submucosa (odds ratio [OR], 25.46; 95% confidence interval [CI], 7.09–91.42), the endoscopic resection was presumed incomplete (OR, 15.55; 95% CI, 4.28–56.56), or the lymph system was invaded (OR, 13.69; 95% CI, 1.76–106.57). Fourteen patients (6.2%) had residual or recurrent malignancies at the site of the previous ECC resection and were significantly associated with presumed incomplete endoscopic resection (OR, 4.59; 95% CI, 1.21–17.39) and submucosal invasion (OR, 5.14; 95% CI, 1.18–22.34).
Conclusions
Subsequent surgery was associated with submucosa invasion, lymphatic invasion, and cancer-positive margins. Presumed completeness of the resection may be helpful for guiding the subsequent management of patients who undergo endoscopic resection of ECC. -
Citations
Citations to this article as recorded by- Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma
Hyun Jin Bae, Hoyeon Ju, Han Hee Lee, Jinsu Kim, Bo-In Lee, Sung Hak Lee, Daeyoun David Won, Yoon Suk Lee, In Kyu Lee, Young-Seok Cho
Surgical Endoscopy.2023; 37(2): 1231. CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Comparison of long-term recurrence-free survival between primary surgery and endoscopic resection followed by secondary surgery in T1 colorectal cancer
Eun Hye Oh, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Jin Cheon Kim, Jeong-Sik Byeon
Gastrointestinal Endoscopy.2021; 94(2): 394. CrossRef - Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2020; 18(1): 96. CrossRef
- Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma
- 7,879 View
- 168 Download
- 3 Web of Science
- 4 Crossref
- Inflammatory bowel diseases
- Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
- Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
- Intest Res 2019;17(4):504-515. Published online August 23, 2019
- DOI: https://doi.org/10.5217/ir.2019.00030
-
Abstract
PDFPubReaderePub
- Background/Aims
An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease.
Methods
Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018.
Results
Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn’s disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group.
Conclusions
In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease. -
Citations
Citations to this article as recorded by- Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
Tsubasa Oike, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Sadahisa Ogasawara, Tomoaki Matsumura, Tomoo Nakagawa, Makoto Arai, Tatsuro Katsuno, Yoshihiro Fukuda, Yoshio K
Arab Journal of Gastroenterology.2024; 25(3): 257. CrossRef - Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease
Gary R. Lichtenstein, Arif Soonasra, Mark Latymer, Sheena Singh, Brian G. Feagan
Expert Opinion on Biological Therapy.2024; 24(7): 691. CrossRef - Clinical experience of using biosimilars in Crohn’s disease and their effectiveness
Léa Sequier, Bénédicte Caron, Silvio Danese, Laurent Peyrin-Biroulet
Expert Opinion on Biological Therapy.2024; : 1. CrossRef - Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
Journal of Clinical Gastroenterology.2023; 57(6): 601. CrossRef - Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study
Tomoe Kazama, Katsuyoshi Ando, Nobuhiro Ueno, Mikihiro Fujiya, Takahiro Ito, Atsuo Maemoto, Keisuke Ishigami, Masanori Nojima, Hiroshi Nakase, Shintaro Sagami
PLOS ONE.2023; 18(9): e0288393. CrossRef - Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Akimichi Morita, Mamitaro Ohtsuki, Yasuo Suzuki, Mamoru Watanabe, Hisashi Yamanaka, Toshifumi Hibi
Drug Safety.2023; 46(10): 991. CrossRef - Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics
Tsutomu Takeuchi, Kiyohiro Nishikawa, Fumika Yamada, Shiro Ohshima, Makoto Inoue, Yutaka Yoshioka, Hisashi Yamanaka
Modern Rheumatology.2022; 32(4): 718. CrossRef - Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Bincy Abraham, Bertus Eksteen, Khan Nedd, Hrishikesh Kale, Dipen Patel, Jennifer Stephens, Ahmed Shelbaya, Richard Chambers, Arif Soonasra
Advances in Therapy.2022; 39(5): 2109. CrossRef - Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
Akimichi Morita, Kiyohiro Nishikawa, Fumika Yamada, Keiichi Yamanaka, Hideki Nakajima, Mamitaro Ohtsuki
The Journal of Dermatology.2022; 49(10): 957. CrossRef - Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
Shintaro Sagami, Kiyohiro Nishikawa, Fumika Yamada, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(8): 2091. CrossRef - Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
Current Medical Research and Opinion.2021; 37(9): 1529. CrossRef - Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness
Jae Hee Cheon, Seongsu Nah, Hyoun Woo Kang, Yun Jeong Lim, Sang-Hoon Lee, Sang Joon Lee, Sung Hyun Kim, Na Hyun Jung, Jeong Eun Park, Yeo Jin Lee, Da Bee Jeon, Yeon Mi Lee, Jong Min Kim, Sung-Hwan Park
Advances in Therapy.2021; 38(8): 4366. CrossRef - The Great Debate With IBD Biosimilars
Jimmy K Limdi, Francis A Farraye
Crohn's & Colitis 360.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning, Rita L. Hui
BioDrugs.2020; 34(3): 395. CrossRef - Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies
Sang Joon Lee, KyungMin Baek, Sujin Lee, Yoon Jee Lee, Jeong Eun Park, Seul Gi Lee
BioDrugs.2020; 34(4): 513. CrossRef - Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update
Michele S. Barnhill, Joshua M. Steinberg, Joseph J. Jennings, James H. Lewis
Current Gastroenterology Reports.2020;[Epub] CrossRef
- Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
- 8,805 View
- 457 Download
- 16 Web of Science
- 17 Crossref
- Inflammatory bowel diseases
- Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study
- Jingzhou Wang, Takahiro I Nakamura, Anne G Tuskey, Brian W Behm
- Intest Res 2019;17(4):496-503. Published online October 14, 2019
- DOI: https://doi.org/10.5217/ir.2019.00050
-
Abstract
PDFPubReaderePub
- Background/Aims
Polypharmacy is a common clinical problem with chronic diseases that can be associated with adverse patient outcomes. The present study aimed to determine the prevalence and patient-specific characteristics associated with polypharmacy in an ulcerative colitis (UC) population and to assess the impact of polypharmacy on disease outcomes.
Methods
A retrospective chart review of patients with UC who visited a tertiary medical center outpatient clinic between 2006 and 2011 was performed. Polypharmacy was defined as major ( ≥ 5 non-UC medications) or minor (2–4 non-UC medications). UC medications were excluded in the polypharmacy grouping to minimize the confounding between disease severity and polypharmacy. Outcomes of interest include disease flare, therapy escalation, UC-related hospitalization, and surgery within 5 years of the initial visit.
Results
A total of 457 patients with UC were eligible for baseline analysis. Major polypharmacy was identified in 29.8% of patients, and minor polypharmacy was identified in 40.9% of the population. Polypharmacy at baseline was associated with advanced age (P< 0.001), female sex (P= 0.019), functional gastrointestinal (GI) disorders (P< 0.001), and psychiatric disease (P< 0.001). Over 5 years of follow-up, 265 patients remained eligible for analysis. After adjusting for age, sex, functional GI disorders, and psychiatric disease, major polypharmacy was found to be significantly associated with an increased risk of disease flare (odds ratio, 4.00; 95% confidence interval, 1.66–9.62). However, major polypharmacy was not associated with the risk of therapy escalation, hospitalization, or surgery.
Conclusions
Polypharmacy from non-inflammatory bowel disease medications was present in a substantial proportion of adult patients with UC and was associated with an increased risk of disease flare. -
Citations
Citations to this article as recorded by- In vitro safety signals for potential clinical development of the anti-inflammatory pregnane X receptor agonist FKK6
Zdeněk Dvořák, Barbora Vyhlídalová, Petra Pečinková, Hao Li, Pavel Anzenbacher, Alena Špičáková, Eva Anzenbacherová, Vimanda Chow, Jiabao Liu, Henry Krause, Derek Wilson, Tibor Berés, Petr Tarkowski, Dajun Chen, Sridhar Mani
Bioorganic Chemistry.2024; 144: 107137. CrossRef - A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel disease
Sivan Harnik, Bella Ungar, Ronen Loebstein, Shomron Ben‐Horin
United European Gastroenterology Journal.2024; 12(5): 627. CrossRef - Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef - Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets
Ekaterina Safroneeva, Helen Thorne, Ortrud Gerstner, Raphaël Laoun
Inflammatory Bowel Diseases.2024;[Epub] CrossRef - Severe Polypharmacy Increases Risk of Hospitalization Among Older Adults With Inflammatory Bowel Disease
Darren Drittel, William Schreiber-Stainthorp, Olivia Delau, Sakteesh V. Gurunathan, Joshua Chodosh, Dorry L. Segev, Mara McAdams-DeMarco, Seymour Katz, John Dodson, Aasma Shaukat, Adam S. Faye
American Journal of Gastroenterology.2024;[Epub] CrossRef - Factors contributing to flares of ulcerative colitis in North India- a case-control study
Vishavdeep Singh Rana, Gaurav Mahajan, Amol N. Patil, Anupam K. Singh, Vaneet Jearth, Aravind Sekar, Harjeet Singh, Atul Saroch, Usha Dutta, Vishal Sharma
BMC Gastroenterology.2023;[Epub] CrossRef - Worldwide Prevalence of Polypharmacy: A Systematic Review
Beatriz Dias Januário, Natália Silva Mafra, Humberto de Souza Silva, Isabella Monteiro Carvalho, Ana Luiza Sobreira Sena, Ana Paula Gomes Soares Pereira, Newton Santos de Faria Júnior, Helton Oliveira Campos
Current Drug Metabolism.2023; 24(8): 568. CrossRef - Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease
Vera E.R. Asscher, Sanne N. Waars, Andrea E. van der Meulen-de Jong, Rogier J.L. Stuyt, A. Martine C. Baven-Pronk, Sander van der Marel, Rutger J. Jacobs, Jeoffrey J.L. Haans, Lennart J. Meijer, Jacqueline D. Klijnsma-Slagboom, Marijn H. Duin, Milou E.R.
Clinical Gastroenterology and Hepatology.2022; 20(5): e1006. CrossRef - Health Care Costs and Resource Utilization Among Patients With Crohn’s Disease With and Without Perianal Fistula
Grace Chen, Vasantha Pedarla, Kyle D Null, Susan E Cazzetta, Qasim Rana Khan, David A Schwartz
Inflammatory Bowel Diseases.2022; 28(6): 870. CrossRef - The 5Ms of Geriatrics in Gastroenterology: The Path to Creating Age-Friendly Care for Older Adults With Inflammatory Bowel Diseases and Cirrhosis
Bharati Kochar, Nneka N. Ufere, Christine S. Ritchie, Jennifer C. Lai
Clinical and Translational Gastroenterology.2022; 13(1): e00445. CrossRef - Polypharmacy in Patients With Inflammatory Bowel Disease
Francisco Mesonero, Cristina Fernández, Eugenia Sánchez-Rodríguez, Ana García-García Paredes, Carla Senosiain, Agustín Albillos, Antonio López-Sanromán
Journal of Clinical Gastroenterology.2022; 56(3): e189. CrossRef - Is it time to include older adults in inflammatory bowel disease trials? A call for action
Sophie Vieujean, Bénédicte Caron, Vipul Jairath, Athanase Benetos, Silvio Danese, Edouard Louis, Laurent Peyrin-Biroulet
The Lancet Healthy Longevity.2022; 3(5): e356. CrossRef - Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases – A Systematic Review and Meta-Analysis
Laura Arp, Sabine Jansson, Vibeke Wewer, Johan Burisch
Journal of Crohn's and Colitis.2022; 16(12): 1933. CrossRef - Impact of isotretinoin on inflammatory bowel disease flare in patients with preexisting inflammatory bowel disease diagnosis: A cross-sectional study
Christina G. Lopez, Ruby Kwak, Lindsay McCormack, Guohai Zhou, Alexandra Charrow
Journal of the American Academy of Dermatology.2022; 87(6): 1399. CrossRef - Systematic review with meta‐analysis: dietary intake in adults with inflammatory bowel disease
Kelly Lambert, Daniel Pappas, Chiara Miglioretto, Arefeh Javadpour, Hannah Reveley, Laura Frank, Michael C. Grimm, Dorit Samocha‐Bonet, Georgina L. Hold
Alimentary Pharmacology & Therapeutics.2021; 54(6): 742. CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Frailty in inflammatory bowel diseases: an emerging concept
Bharati Kochar, Ariela R. Orkaby, Ashwin N. Ananthakrishnan, Christine S. Ritchie
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
Jongwook Yu, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Gut and Liver.2021; 15(6): 858. CrossRef - Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions
Vanessa DeClercq, Jacob T. Nearing, Morgan G. I. Langille, Jonathan Jacobs
PLOS ONE.2021; 16(12): e0261032. CrossRef
- In vitro safety signals for potential clinical development of the anti-inflammatory pregnane X receptor agonist FKK6
- 6,899 View
- 176 Download
- 18 Web of Science
- 19 Crossref
- Inflammatory bowel diseases
- Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
- Rupa Banerjee, Partha Pal, Susan Hutfless, B Girish Ganesh, D Nageshwar Reddy
- Intest Res 2019;17(4):486-495. Published online August 6, 2019
- DOI: https://doi.org/10.5217/ir.2018.00174
-
Abstract
PDFPubReaderePub
- Background/Aims
Information about familial aggregation of inflammatory bowel disease (IBD) in Asia is limited. We aimed to analyze the prevalence and risk of familial IBD in an Indian cohort and compare familial and sporadic cases.
Methods
Familial IBD cases were identified from a large prospectively maintained IBD registry. The prevalence of IBD in first- and seconddegree relatives of index cases was evaluated. The disease behavior was compared to that of sporadic cases.
Results
Total 3,553 patients (ulcerative colitis [UC], 2,053; Crohn’s disease [CD], 1,500) were included. Familial IBD was noted in 4.13% of CD and 4.34% of UC patients. Family history was commoner in pediatric group (< 18 years) (P= 0.0002; odds ratio [OR], 2.8; 95% confidence interval [CI], 1.6–4.8). Majority had paternal transmission (UC, 67.42%; CD, 70.97%). Concordance of disease type was higher in UC (79.7%) compared to CD (37.1%). Familial IBD was associated with higher cumulative relapse rate (CD, P< 0.001; UC, P< 0.001), higher cumulative rate of surgery (CD, P< 0.001; UC, P< 0.001) and higher rate of biologic use (CD, P= 0.010; UC, P= 0.015). Pan-colitis was higher in familial UC (P= 0.003; OR, 1.935; 95% CI, 1.248–3.000). Fistulizing disease was commoner in familial CD (P= 0.041; OR, 2.044; 95% CI, 1.030–4.056).
Conclusions
The prevalence of familial IBD in India appears comparable to rest of Asia but lower than the West. It is associated with a younger age of onset, higher incidence of pan-colitis in UC and fistulizing complications in CD. Familial IBD has higher cumulative relapse, surgery and biologic use rates. Hence, family history of IBD could have important prognostic implications. -
Citations
Citations to this article as recorded by- Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India
Neelam Mohan, Shivani Deswal, Anubhuti Bhardwaj
Indian Journal of Gastroenterology.2024; 43(1): 208. CrossRef - Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project
Carlos González-Muñoza, Margalida Calafat, Javier P Gisbert, Eva Iglesias, Miguel Mínguez, Beatriz Sicilia, Montserrat Aceituno, Fernando Gomollón, Xavier Calvet, Elena Ricart, Luisa De Castro, Montserrat Rivero, Francisco Mesonero, Lucía Márquez, Pilar N
Postgraduate Medical Journal.2024;[Epub] CrossRef - Differences of clinical phenotype between familial and sporadic Crohn’s disease in East China
Siyuan Dong, Xiaoxia Xiang, Yu Zhang, Rongbei Liu, Lingna Ye, Qian Cao
International Journal of Colorectal Disease.2024;[Epub] CrossRef - Inflammatory bowel disease in families with four or more affected first-degree relatives
Elad Boaz, Ariella Bar-Gil Shitrit, Menachem Schechter, Eran Goldin, Petachia Reissman, Shlomo Yellinek, Benjamin Koslowsky
Scandinavian Journal of Gastroenterology.2023; 58(1): 20. CrossRef - Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases
Bahar Saberzadeh-Ardestani, Amir Anushiravani, Fariborz Mansour-Ghanaei, Hafez Fakheri, Homayoon Vahedi, Farshad Sheikhesmaeili, Abbas Yazdanbod, Seyed Hamid Moosavy, Hasan Vosoghinia, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Masoud Malek
Inflammatory Bowel Diseases.2022; 28(7): 1004. CrossRef - Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
Journal of Gastroenterology and Hepatology.2022; 37(6): 1004. CrossRef - Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef - What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef - Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61. CrossRef - Following the Indian Immigrant: adoption of westernization results in a western gut microbiome and an increased risk of inflammatory bowel diseases
Leah D D'Aloisio, Vignesh Shetty, Mamatha Ballal, Deanna L Gibson
FEMS Microbiology Ecology.2022;[Epub] CrossRef - Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease
Rupa Banerjee, Partha Pal, Bhargavi Adigopula, Duvvuru Nageshwar Reddy
Journal of Clinical Gastroenterology.2021; 55(10): e92. CrossRef - Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intestinal Research.2021; 19(4): 398. CrossRef - Inflammatory bowel diseases in Tamil Nadu: A survey of demographics, clinical profile, and practices
Rohan V Yewale, Kartik Natarajan, Jeyaraj Ubal Dhus, Sarojini Ashok Parameswaran, Kallipatti Ramaswamy Palaniswamy, Doraisamy Babu Vinish, Aravindh Somasundaram, Arulraj Ramakrishnan, Sibithooran Karmegam, Ramaswamy Saraswathy Arun, Ujjani Shankaraiah Man
JGH Open.2021; 5(11): 1306. CrossRef - Inflammatory Bowel Diseases in South Asian Patients: Underappreciated and Understudied
Bharati Kochar
Inflammatory Bowel Diseases.2020; 26(12): 1943. CrossRef - Family History of Diabetes is Associated with Increased Risk of Recurrent Diabetic Ketoacidosis in Pediatric Patients
Janaki D. Vakharia, Sungeeta Agrawal, Janine Molino, Lisa Swartz Topor
Endocrine Practice.2020; 26(3): 305. CrossRef - Paediatric inflammatory bowel disease in India: a prospective multicentre study
Anshu Srivastava, Malathi Sathiyasekharan, Barath Jagadisan, Rishi Bolia, Maya Peethambaran, Geetha Mammayil, Bhaswati Acharya, Rohan Malik, Srinivas Sankaranarayanan, Vishnu Biradar, Smita Malhotra, Mathew Philip, Ujjal Poddar, Surender Kumar Yachha
European Journal of Gastroenterology & Hepatology.2020; 32(10): 1305. CrossRef
- Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India
- 7,044 View
- 164 Download
- 18 Web of Science
- 18 Crossref
- Inflammatory bowel diseases
- Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
- Tadahiro Yanagi, Kosuke Ushijima, Hidenobu Koga, Takeshi Tomomasa, Hitoshi Tajiri, Reiko Kunisaki, Takashi Isihige, Hiroyuki Yamada, Katsuhiro Arai, Atsushi Yoden, Tomoki Aomatsu, Satoru Nagata, Keiichi Uchida, Yoshikazu Ohtsuka, Toshiaki Shimizu
- Intest Res 2019;17(4):476-485. Published online August 31, 2019
- DOI: https://doi.org/10.5217/ir.2019.00027
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.
Methods
We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.
Results
Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.
Conclusions
Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children. -
Citations
Citations to this article as recorded by- Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis
Perseus V. Patel, Amy Zhang, Balu Bhasuran, Vignesh G. Ravindranath, Melvin B. Heyman, Sofia G. Verstraete, Atul J. Butte, Michael J. Rosen, Vivek A. Rudrapatna
Journal of Pediatric Gastroenterology and Nutrition.2024; 78(5): 1126. CrossRef - Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef - Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef - Oral Tacrolimus in Steroid Refractory and Dependent Pediatric Ulcerative Colitis—A Systematic Review and Meta-Analysis
Rishi Bolia, Akhil Goel, Pooja Semwal, Anshu Srivastava
Journal of Pediatric Gastroenterology & Nutrition.2023; 77(2): 228. CrossRef - Tacrolimus as an alternative treatment for patients with juvenile idiopathic arthritis
Susumu Yamazaki, Masaki Shimizu, Yuko Akutsu, Asami Shimbo, Masaaki Mori
Modern Rheumatology.2022; 32(4): 783. CrossRef - 3D printed tacrolimus suppositories for the treatment of ulcerative colitis
Iria Seoane-Viaño, Jun Jie Ong, Asteria Luzardo-Álvarez, Miguel González-Barcia, Abdul W. Basit, Francisco J. Otero-Espinar, Alvaro Goyanes
Asian Journal of Pharmaceutical Sciences.2021; 16(1): 110. CrossRef - Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intestinal Research.2021; 19(4): 357. CrossRef - Tacrolimus in pediatric ulcerative colitis: does it have a role?
Seung Kim
Intestinal Research.2019; 17(4): 441. CrossRef
- Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis
- 13,385 View
- 232 Download
- 10 Web of Science
- 8 Crossref
Focused Reviews
- IBD
- Nutritional approach as therapeutic manipulation in inflammatory bowel disease
- Jin Young Yoon
- Intest Res 2019;17(4):463-475. Published online October 28, 2019
- DOI: https://doi.org/10.5217/ir.2019.00078
-
Abstract
PDFPubReaderePub
- Malnutrition is observed more frequently in patients with inflammatory bowel disease (IBD) than in the general population and associated with adverse clinical outcomes. This study aimed to review the current knowledge regarding the efficacy of dietary and nutritional intervention in IBD patients. Exclusive enteral nutrition might be inferior to corticosteroid treatment in adults with active Crohn’s disease (CD) but might even be superior considering the adverse effects of corticosteroid treatment in children. Total parenteral nutrition has no advantage over enteral nutrition, which is considered a more physiologic modality in organ function. Current guidelines do not yet recommend ω3-polyunsaturated fatty acid supplementation for the prevention and maintenance of remission in IBD patients. Dietary fiber supplementation could be effective in the relief of symptoms and maintenance of remission in ulcerative colitis (UC). Although vitamin D may be favorable to clinical course of IBD and bone density. Probiotic supplementation has proven to be effective in preventing and treating pouchitis for UC but is less effective in treating CD. Nutritional interventions not only correct nutritional deficiencies but also improve symptoms and clinical courses of the disease. Hence, nutritional approaches need to be developed to significantly evaluate the effectiveness of dietary interventions used to treat IBD.
-
Citations
Citations to this article as recorded by- Parenteral Nutrition, Inflammatory Bowel Disease, and Gut Barrier: An Intricate Plot
Carlo Covello, Guia Becherucci, Federica Di Vincenzo, Angelo Del Gaudio, Marco Pizzoferrato, Giovanni Cammarota, Antonio Gasbarrini, Franco Scaldaferri, Maria Chiara Mentella
Nutrients.2024; 16(14): 2288. CrossRef - Association of selected adipokines with vitamin D deficiency in children with inflammatory bowel disease
Milos Geryk, Veronika Kucerova, Maria Velganova-Veghova, Hana Foltenova, Katerina Bouchalova, David Karasek, Martin Radvansky, Eva Karaskova
BMC Pediatrics.2024;[Epub] CrossRef - Self-reported food intolerance, dietary supplement use and malnutrition in chronic inflammatory bowel diseases: Findings from a cross-sectional study in Lebanon
Maha Hoteit, Nour Ftouni, Malak Olayan, Souheil Hallit, Joya Maria Karam, Mahmoud Hallal, Samer Hotayt, Bilal Hotayt, Imad Al Kassaa
PLOS ONE.2024; 19(7): e0305352. CrossRef - Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice
Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, Yih Jong Chern, Yu-Jen Hsu, Shu-Huan Huang, Wen-Sy Tsai
Intestinal Research.2023; 21(1): 100. CrossRef - İnflamatuvar bağırsak hastalıklarında hastalığa özgü aktivite indeksinin depresyon ve inflamatuvar belirteçler ile ilişkisi
Büşra YÜKSEL, Sinem BAYRAM, Mehmet CİNDORUK, Harun KÜÇÜK
Akademik Gastroenteroloji Dergisi.2022; 21(1): 15. CrossRef - Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intestinal Research.2022; 20(3): 321. CrossRef - COVID-19 and immunomodulation in IBD
Markus F Neurath
Gut.2020; 69(7): 1335. CrossRef
- Parenteral Nutrition, Inflammatory Bowel Disease, and Gut Barrier: An Intricate Plot
- 8,842 View
- 233 Download
- 7 Web of Science
- 7 Crossref
- Colorectal neoplasia
- Nutritional issues in patients with cancer
- Duk Hwan Kim
- Intest Res 2019;17(4):455-462. Published online October 14, 2019
- DOI: https://doi.org/10.5217/ir.2019.00076
-
Abstract
PDFPubReaderePub
- Cancer is a catabolic inflammatory disease that causes patients to often experience weight loss, or even cachexia in severe cases. Undernourishment in patients with cancer impairs the quality of life and therapeutic response, further leading to poor prognosis. Active and frequent nutritional screening and assessment using valid tools are important for fast and appropriate nutritional intervention. Additionally, a suitable individualized nutritional intervention strategy should be established based on the nutritional assessment result. In general, nutritional intervention begins with nutritional counseling of patients diagnosed with cancer, and a well-planned nutritional counseling improves the treatment adherence and nutritional status. When planning nutritional supplementation for cancer patients, specific nutrients, including amino acids and fatty acids, should be considered. However, there has been no consistent result showing that any particular nutrient significantly improves the prognosis of cancer patients. Hence, continuous attention from clinical physicians is needed to plan nutritional improvement in patients with cancer.
-
Citations
Citations to this article as recorded by- Experiences of cancer patients in receiving dietary advice from healthcare professionals and of healthcare professionals in providing this advice—a systematic review
Laura Keaver, Niamh O’Callaghan, Amy E. LaVertu, Cherith J. Semple, Ciara M. Hughes, Jeffrey R. Hanna, Lisa Ryan
Journal of Cancer Survivorship.2024; 18(4): 1211. CrossRef - Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B‐cell lymphoma
Xiaoya Yun, Jiefei Bai, Ru Feng, Jiangtao Li, Ting Wang, Yazi Yang, Jingjing Yin, Long Qian, Shuai Zhang, Qingyun Cao, Xiaoxuan Xue, Hongmei Jing, Hui Liu
Cancer Medicine.2024;[Epub] CrossRef - Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef - Examining the relationship between nutritional status and wound healing in head and neck cancer treatment: A focus on malnutrition and nutrient deficiencies
Yajun Chen, Yuying Li, Yaqi Ceng, Chunlei Li, Yueying Li, Yujie Wang, Kun Wang
International Wound Journal.2024;[Epub] CrossRef - Anti-breast cancer activity of the essential oil from grapefruit mint (Mentha suaveolens × piperita)
Zohreh Jahanafrooz, Mir Mohammad Hossein Mousavi, Soghra Akbarzadeh, Maedeh Hemmatzadeh, Filippo Maggi, Mohammad Reza Morshedloo
Fitoterapia.2024; 174: 105875. CrossRef - Accompagnement alimentaire du cancéreux, lutte contre les dégoûts et aversions
Philippe Pouillart
Pratiques en nutrition.2024; 20(78): 14. CrossRef - Exome-Based Amino Acid Optimization: A Dietary Strategy to Satisfy Human Nutritional Demands and Enhance Muscle Strength in Breast Tumor Mice Undergoing Chemotherapy
Congcong Gong, Chunwei Jiao, Huijia Liang, Yuxin Ma, Qingping Wu, Yizhen Xie
Journal of Agricultural and Food Chemistry.2024; 72(13): 7089. CrossRef - Prehabilitation and its Outcomes in Cancer Patients: A Narrative Review
A. J. Rajendran, M. A. Raja, S. Benedic Kingslin Suresh
Indian Journal of Physical Medicine and Rehabilitation.2024; 34(1): 5. CrossRef - Nutritional Experiences and Perceptions of Breast Cancer Patients Receiving Chemotherapy: A Qualitative Study
Sema Koçan, Canan Altınsoy, Yağmur Demirel Özbek
Ordu Üniversitesi Hemşirelik Çalışmaları Dergisi.2024; 7(2): 358. CrossRef - Adopting a systems-thinking approach to optimise dietary and exercise referral practices for cancer survivors
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Fiona Crawford-Williams, Matthew P. Wallen, Reegan Knowles, Chad Y. Han, Vivienne Milch, Justin J. Holland, Raymond J. Chan
Supportive Care in Cancer.2024;[Epub] CrossRef - Thoracic CT imaging in obesity: Technical challenges, imaging findings and future outlook
Perawish Suwathep, Alexander Sheeka, Susan Copley
Meta-Radiology.2024; 2(3): 100100. CrossRef - Evaluating the Outcomes in Patients with Colorectal Cancer Using the Malnutrition Universal Screening Tool: A Systematic Review
Calin Muntean, Andiana Roxana Blidari, Alaviana Monique Faur, Razvan Ovidiu Curca, Catalin Vladut Ionut Feier
Journal of Multidisciplinary Healthcare.2024; Volume 17: 4277. CrossRef - Effects of Five-Step Nutritional Interventions Conducted by a Multidisciplinary Care Team on Gastroenteric Cancer Patients Undergoing Chemotherapy: A Randomized Clinical Trial
Lijia Chen, Minyan Zhao, Liping Tan, Yusong Zhang
Nutrition and Cancer.2023; 75(1): 197. CrossRef - Effectiveness of mHealth diet interventions in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
Yabo Gong, Xiaohan Jiang, Xijie Chen, Shi Chen, Yuee Wen, Xiuhong Yuan, Jiamin Chen, Junsheng Peng
Asia-Pacific Journal of Oncology Nursing.2023; 10(3): 100196. CrossRef - Mapping the global research landscape on nutritional support for patients with gastrointestinal malignancy: visualization analysis
Muna Shakhshir, Amani S. Abushanab, Amer Koni, Abdelkarim Barqawi, Khaled Demyati, Samah W. Al-Jabi, Sa’ed H. Zyoud
Supportive Care in Cancer.2023;[Epub] CrossRef - Prognostic significance of controlling nutritional status score for patients with gastric cancer: A systematic review and meta‑analysis
Jian Yin, Jin Qu, Xiaoxiao Liang, Meimei Wang
Experimental and Therapeutic Medicine.2023;[Epub] CrossRef - Web-based nutrition: a useful resource for cancer patients?
Diana Elena Lazar, Roxana Postolica, Bianca Hanganu, Veronica Mocanu, Beatrice Gabriela Ioan
Frontiers in Nutrition.2023;[Epub] CrossRef - Depression and Anxiety Mediate the Associations between Nutritional Status, Functional Capacity, and Quality of Life in Patients with Cancer
Iliana Evangelou, Konstantina Vamvakari, Ioanna Panagiota Kalafati, Michail Kipouros, Arezina N. Kasti, Rena I. Kosti, Fotini Bonoti, Odysseas Androutsos
Nutrition and Cancer.2023; 75(9): 1783. CrossRef - Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study
Enrique Grande, Fernando Moreno, José Trigo, Jaume Capdevila, Jimena Abilés, Mariola Sirvent, Margarita Garrido-Siles, Gabriel Olveira, Julia Ocón, Maria Luisa Fernández Soto
Supportive Care in Cancer.2023;[Epub] CrossRef - Anti-Cancer Properties of Flaxseed Proteome
Yulia Merkher, Elizaveta Kontareva, Anastasia Alexandrova, Rajesha Javaraiah, Margarita Pustovalova, Sergey Leonov
Proteomes.2023; 11(4): 37. CrossRef - Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors
Salvatore Artale, Sabrina Barzaghi, Nunziata Grillo, Claudia Maggi, Stefano Lepori, Chiara Butti, Antonella Bovio, Lucia Barbarini, Andrea Colombo, Laura Zanlorenzi, Elena Castiglioni, Alessandra Trojani
Nutrition and Cancer.2022; 74(1): 2. CrossRef - Chronic Inflammation in Obesity and Cancer Cachexia
Rosa Divella, Gennaro Gadaleta Caldarola, Antonio Mazzocca
Journal of Clinical Medicine.2022; 11(8): 2191. CrossRef - A Nutrition and Inflammation-Related Nomogram to Predict Overall Survival in Surgically Resected Esophageal Squamous Cell Carcinoma (ESCC) Patients
Juan Li, Xinyu Mei, Di Sun, Mingfa Guo, Mingran Xie, Xia Chen
Nutrition and Cancer.2022; 74(5): 1625. CrossRef - Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives
Ria Joseph, Nicolas H. Hart, Natalie Bradford, Oluwaseyifunmi Andi Agbejule, Bogda Koczwara, Alexandre Chan, Matthew P. Wallen, Raymond J. Chan
Supportive Care in Cancer.2022; 30(10): 8429. CrossRef - MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review)
Xin Li, Lidong Du, Qiang Liu, Zhong Lu
Experimental and Therapeutic Medicine.2022;[Epub] CrossRef - Nutritional risk screening in malignant tumors: a study of 375 cancer inpatients
Min Zhang, Yuying Guo, Xiaodi Zhang, Yu Zhang, Yuanyuan Fan, Yanting Liu, Kelei Zhao, Ruijuan Fan, Ping Lu
Supportive Care in Cancer.2022; 30(10): 8333. CrossRef - Prognostic Value of the Pre-Treatment Prognostic Nutritional Index for Patients with Unresectable Locally-Advanced and Advanced Stage Upper Gastrointestinal Tract Cancer
Chaichana Chantharakhit, Nantapa Sujaritvanichpong, Chanachai Chantharakhit
International Journal of General Medicine.2022; Volume 15: 6681. CrossRef - Visceral fat area and albumin based nutrition-related prognostic index model could better stratify the prognosis of diffuse large B-cell lymphoma in rituximab era
Ziyuan Shen, Lingling Hu, Shuo Zhang, Qian Sun, Weidong Li, Dongmei Yan, Guoqi Cai, Wei Sang
Frontiers in Nutrition.2022;[Epub] CrossRef - Malnutrition induced by cancer and oncology treatment
Jelena Kostadinović, Jelena Kotur-Stevuljević, Nevena Ivanović, Zoran Andrić
Hrana i ishrana.2022; 63(1): 9. CrossRef - Irish cancer patients and survivors have a positive view of the role of nutritional care in cancer management from diagnosis through survivorship
Laura Keaver
Irish Journal of Medical Science (1971 -).2021; 190(4): 1387. CrossRef - Nutrition intervention is beneficial to the quality of life of patients with gastrointestinal cancer undergoing chemotherapy in Vietnam
Linh Thuy Nguyen, Anh Kim Dang, Phuong Thi Duong, Hanh Bich Thi Phan, Chinh Tuyet Thi Pham, Anh Tuan Le Nguyen, Huong Thi Le
Cancer Medicine.2021; 10(5): 1668. CrossRef - Managing the effects of cancer and cancer treatments on patients’ nutritional status
Kathell Margaret Geraghty
Nursing Standard.2021; 36(3): 54. CrossRef - Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors
Joshua P. Kronenfeld, Kristi D. Graves, Frank J. Penedo, Betina Yanez
The Oncologist.2021; 26(6): 443. CrossRef - Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?
Dana A. M. Mustafa, Lawlaw Saida, Diba Latifi, Leonoor V. Wismans, Willem de Koning, Lona Zeneyedpour, Theo M. Luider, Bernadette van den Hoogen, Casper H. J. van Eijck
Cancers.2021; 13(12): 2896. CrossRef - Detection of Lung Cancer via Blood Plasma and 1H-NMR Metabolomics: Validation by a Semi-Targeted and Quantitative Approach Using a Protein-Binding Competitor
Elien Derveaux, Michiel Thomeer, Liesbet Mesotten, Gunter Reekmans, Peter Adriaensens
Metabolites.2021; 11(8): 537. CrossRef - Short Nutritional Assessment Questionnaire as a predictor of undernutrition in cancer patients receiving outpatient chemotherapy: A retrospective study
Kiyomi Harada, Masami Okagaki, Hiroko Neriya, Kengo Yoshii, Keiko Sekido, Akane Higashi
European Journal of Oncology Nursing.2021; 54: 102013. CrossRef - A Quasi-Experimental Study of the Effect of Ginger Tea on Preventing Nausea and Vomiting in Patients With Gynecological Cancers Receiving Cisplatin-Based Regimens
Dhuha Y. Wazqar, Hala A. Thabet, Amany M. Safwat
Cancer Nursing.2021; 44(6): E513. CrossRef - Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials
Elwira Gliwska, Dominika Guzek, Zuzanna Przekop, Jacek Sobocki, Dominika Głąbska
Nutrients.2021; 13(12): 4551. CrossRef - Nutritional Status of Patients with Nasopharyngeal Carcinoma
Yussy Afriani Dewi, Arief Fakhrizal, Shinta Fitri Boesoirie, Ayu Hardianti Saputri
Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1435. CrossRef - Bilayer Mucoadhesive Buccal Film for Mucosal Ulcers Treatment: Development, Characterization, and Single Study Case
Thais F. R. Alves, Alesssandra C. Rios, Katiusca da Silva Pontes, Decio L. Portella, Norberto Aranha, Patricia Severino, Eliana B. Souto, Joyce K. M. Gonsalves, Rogeria de Souza Nunes, Marco V. Chaud
Pharmaceutics.2020; 12(7): 657. CrossRef - A Study on Challenges to Health Care Delivery Faced by Cancer Patients in India During the COVID-19 Pandemic
Manasij Mitra, Maitraye Basu
Journal of Primary Care & Community Health.2020;[Epub] CrossRef - Enteral feed based gradual improvement of body mass index and normalization of micronutrients in children with malnutrition
Meryem KEÇELİ BAŞARAN, Nur ZENGIN, Ali DOĞAN, Alihan SURSAL, Fatih OZDENER
Journal of Surgery and Medicine.2020; 4(9): 826. CrossRef - Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study
Mohammad Morshad Alam, Tania Rahman, Zinia Afroz, Promit Ananyo Chakraborty, Abrar Wahab, Sanjana Zaman, Mohammad Delwer Hossain Hawlader
Heliyon.2020; 6(10): e05250. CrossRef - Altered Preoperative Nutritional Status in Colorectal Cancer: A Not So Infrequent Issue
Javier Páramo-Zunzunegui, Araceli Ramos-Carrasco, Marcos Alonso-García, Rosa Cuberes-Montserrat, Gil Rodríguez-Caravaca, Manuel Durán-Poveda, María Ximena Silveyra
Journal of Nutrition and Metabolism.2020; 2020: 1. CrossRef - Impact of Early Incorporation of Nutrition Interventions as a Component of Cancer Therapy in Adults: A Review
Julie Richards, Mary Beth Arensberg, Sara Thomas, Kirk W. Kerr, Refaat Hegazi, Michael Bastasch
Nutrients.2020; 12(11): 3403. CrossRef
- Experiences of cancer patients in receiving dietary advice from healthcare professionals and of healthcare professionals in providing this advice—a systematic review
- 8,912 View
- 364 Download
- 41 Web of Science
- 45 Crossref
- Microbiota
- Importance of nutritional therapy in the management of intestinal diseases: beyond energy and nutrient supply
- Seong-Eun Kim
- Intest Res 2019;17(4):443-454. Published online September 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00075
-
Abstract
PDFPubReaderePub
- The gut is an immune-microbiome-epithelial complex. Gut microbiome-host interactions have widespread biological implications, and the role of this complex system extends beyond the digestion of food and nutrient absorption. Dietary nutrients can affect this complex and play a key role in determining gut homeostasis to maintain host health. In this article, we review various dietary nutrients and their contribution to the pathogenesis and treatment of various intestinal diseases including inflammatory bowel disease, irritable bowel syndrome, colorectal cancer, and diverticulitis, among other such disorders. A better understanding of diet-host-gut microbiome interactions is essential to provide beneficial nutrients for gut health and to limit nutritional hazards to ensure successful nutritional management of gastrointestinal conditions in clinical practice.
-
Citations
Citations to this article as recorded by- TOPICAL ISSUES OF NUTRITION OF PATIENTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
Nikishina S.S.
"Medical & pharmaceutical journal "Pulse".2023; : 17. CrossRef - An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef - Rectal swabs are a reliable method of assessing the colonic microbiome
Greg Turner, Michael O’Grady, Daniel Hudson, Xochitl Morgan, Frank Frizelle, Rachel Purcell
International Journal of Medical Microbiology.2022; 312(2): 151549. CrossRef - Detection of Colistin Sulfate on Piglet Gastrointestinal Tract Microbiome Alterations
Shulin Fu, Yuzhen Yuan, Xinyue Tian, Linglu Zhou, Ling Guo, Dan Zhang, Jing He, Chun Peng, Yinsheng Qiu, Chun Ye, Yu Liu, Bingbing Zong
Veterinary Sciences.2022; 9(12): 666. CrossRef - The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef - EFFECTS OF ADOLESCENTS' NUTRITION ON THEIR QUALITY OF LIFE
Filina I.A., Nikishina S.S., Kulakova A.S.
"Medical & pharmaceutical journal "Pulse".2021; : 13. CrossRef - Faecal Microbiota Microsphere Contributed to Relieving Gut Barrier Damage in Colitis
Shuang Zhen, Cheng Zhao, Xin Zhao, Wu Ji, Jieshou Li
Macromolecular Research.2020; 28(6): 644. CrossRef - Dysregulation of gut microbiome is linked to disease activity of rheumatic diseases
Yanfeng Bao, Chen Dong, Juan Ji, Zhifeng Gu
Clinical Rheumatology.2020; 39(9): 2523. CrossRef
- TOPICAL ISSUES OF NUTRITION OF PATIENTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
- 9,245 View
- 403 Download
- 7 Web of Science
- 8 Crossref
Editorial
- IBD
- Tacrolimus in pediatric ulcerative colitis: does it have a role?
- Seung Kim
- Intest Res 2019;17(4):441-442. Published online October 28, 2019
- DOI: https://doi.org/10.5217/ir.2019.00124
- 4,745 View
- 106 Download
Images of the Issue
- IBD
- A pulmonary nodule in a patient with Crohn’s disease
- Akira Hokama, Shusaku Haranaga, Takanobu Sasaki, Hirofumi Matsumoto, Tetsuya Ohira, Atsushi Iraha, Tetsu Kinjo, Saifun Nahar, Jiro Fujita
- Intest Res 2019;17(3):438-439. Published online February 11, 2019
- DOI: https://doi.org/10.5217/ir.2019.00010
- 5,027 View
- 116 Download
Brief Communication
- Miscellaneous
- Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings
- Janice M. Cho, Laura Pestana, Ryan Pardi, Darrell S. Pardi, Sahil Khanna
- Intest Res 2019;17(3):434-437. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2019.00056
-
PDFPubReaderePub
-
Citations
Citations to this article as recorded by- Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection
Whitfield L. Knapple, David S. Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
Muthukumaran Jayachandran, Shen Qu
Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189. CrossRef - Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease
Raseen Tariq, Molly B Disbrow, John K Dibaise, Robert Orenstein, Srishti Saha, Dipesh Solanky, Edward V Loftus, Darrell S Pardi, Sahil Khanna
Inflammatory Bowel Diseases.2020; 26(9): 1415. CrossRef - Faecal Microbiota Transplantation is Effective for the Initial Treatment of Clostridium difficile Infection: A Retrospective Clinical Review
Niloufar Roshan, Annabel K. Clancy, Thomas J. Borody
Infectious Diseases and Therapy.2020; 9(4): 935. CrossRef
- Retrospective subgroup analysis of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy under enforcement discretion for the prevention of recurrent Clostridioides difficile infection
- 5,353 View
- 96 Download
- 5 Web of Science
- 4 Crossref
First
Prev
